



Clearance of cerebral A β in Alzheimer's disease: reassessing the role of microglia and monocytes

Leah Zuroff^{1,2} · David Daley¹ · Keith L. Black¹ · Maya Koronyo-Hamaoui^{1,3}

Received: 25 August 2016 / Revised: 7 January 2017 / Accepted: 11 January 2017 / Published online: 14 February 2017
© The Author(s) 2017. This article is published with open access at Springerlink.com

Abstract Deficiency in cerebral amyloid β -protein (A β) clearance is implicated in the pathogenesis of the common late-onset forms of Alzheimer's disease (AD). Accumulation of misfolded A β in the brain is believed to be a net result of imbalance between its production and removal. This in turn may trigger neuroinflammation, progressive synaptic loss, and ultimately cognitive decline. Clearance of cerebral A β is a complex process mediated by various systems and cell types, including vascular transport across the blood–brain barrier, glymphatic drainage, and engulfment and degradation by resident microglia and infiltrating innate immune cells. Recent studies have highlighted a new, unexpected role for peripheral monocytes and macrophages in restricting cerebral A β fibrils, and possibly soluble oligomers. In AD transgenic (ADtg) mice, monocyte ablation or inhibition of their migration into the brain exacerbated A β pathology, while blood enrichment with monocytes and their increased recruitment to plaque lesion sites greatly diminished A β burden. Profound neuroprotective effects

in ADtg mice were further achieved through increased cerebral recruitment of myelomonocytes overexpressing A β -degrading enzymes. This review summarizes the literature on cellular and molecular mechanisms of cerebral A β clearance with an emphasis on the role of peripheral monocytes and macrophages in A β removal.

Keywords Neurodegenerative diseases · Amyloid- β protein · A β -degrading enzymes · Innate immune cells · Myelomonocytes · Phagocytosis

Abbreviations

AD	Alzheimer's disease
ADtg	AD transgenic models
A β	Amyloid- β protein
AICD	Amyloid intracellular domain
APP	Amyloid precursor protein
ACE	Angiotensin-converting enzyme
ApoE	Apolipoprotein E
ApoER2	ApoE receptor 2 A
AQP4	Aquaporin 4
ABC	ATP-binding cassette
AV	Autophagic vacuole
BACE1	β -secretase 1
BBB	Blood–brain barrier
CCR2	c-c chemokine receptor type 2
CNS	Central nervous system
CAA	Cerebral amyloid angiopathy
CSF	Cerebrospinal fluid
CMA	Chaperone-mediated autophagy
ECE-1	Endothelin-converting enzyme 1
FAD	Familial Alzheimer's disease
GWAS	Genome-wide association study
GA	Glatiramer acetate
GFP	Green fluorescent protein

This paper is dedicated to the memory of Dr. Salomon Moni Hamaoui and Lillian Jones Black, both of whom died from Alzheimer's disease.

L. Zuroff and D. Daley contributed equally to this manuscript.

✉ Maya Koronyo-Hamaoui
maya.koronyo@cshs.org

¹ Department of Neurosurgery, Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, 127 S. San Vicente, AHSP A8115, Los Angeles, CA 90048, USA

² Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA

³ Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA

HLA	Human leukocyte antigen
pTau	Hyperphosphorylated tau
ITIM	Immunoreceptor tyrosine-based inhibition motif
IDE	Insulin-degrading enzyme
IL-1 β	Interleukin-1 β
IL-10	Interleukin-10
ISF	Interstitial fluid
Iba1	Ionized calcium binding adapter molecule 1
LOAD	Late-onset AD
LPS	Lipopolysaccharide
LRP-1	Low-density lipoprotein-related protein 1
LDLR	Low-density lipoprotein receptor
M-CSF	Macrophage colony-stimulating factor
SCARA1	Macrophage scavenger receptor 1
mTOR	Mammalian target of rapamycin
MMP-9	Matrix metalloproteinase-9
MCP-1	Monocyte chemoattractant protein 1
MOG45D	Myelin oligodendrocyte glycoprotein-derived peptide
NEP	Neprilysin
NFTs	Neurofibrillary tangles
PBMC	Peripheral blood monocyte
PICALM	Phosphatidylinositol binding clathrin assembly protein
PS1;PS2	Presenilin-1 and -2
ptau	Hyperphosphorylated tau protein
ROS	Reactive oxygen species
RAGE	Receptor for advanced glycation end products
RFP	Red fluorescent protein
CD33	Sialic acid-binding immunoglobulin-like lectin 3
SNP	Single nucleotide polymorphism
TLR	Toll-like receptor
TGF- β	Transforming growth factor β
TREM2	Triggering receptor on myeloid cells 2
TNF α	Tumor necrosis factor
UPS	Ubiquitin–proteasome system
VLDLR	Very low-density lipoprotein receptor

Introduction

Alzheimer's disease (AD) is a severe neurodegenerative disorder and the most common form of senile dementia, affecting over 5 million in the United States and 45 million worldwide [1, 2]. AD manifests as a progressive decline in cognitive function and behavior, invariably leading to death [3]. The epidemic of AD is especially damaging to the growing elderly population and the economy that supports them. This immense psychosocial and public health burden calls for a clearer understanding of disease pathophysiology

to facilitate the development and implementation of more effective treatment strategies.


Over the past century, our understanding of the molecular mechanisms underlying the development of AD has greatly expanded. Though still pathological hallmarks, extracellular plaques and intracellular neurofibrillary tangles (NFTs) within the brain [4], comprised, respectively, of amyloid- β protein ($A\beta$) and hyperphosphorylated tau (pTau), no longer describe all pathogenic forms of these proteins. Beyond intracellular threads and tangles, misfolded tau may form extracellular assemblies that propagate through and disrupt synaptically dense regions [5, 6]. Meanwhile, extracellular and intracellular oligomers of $A\beta$ were also found to be highly synaptotoxic and exist in a highly dynamic equilibrium between the small, soluble forms and the larger, insoluble intermediates and fibrils [7, 8]. Recent exploration of this disease outside the brain, in another central nervous system tissue, has further revealed $A\beta$ pathology in the retina of AD patients, including those at early stages [9–13]. Converging data from genetic, physiologic, biochemical, and clinical studies demonstrate a strong association between $A\beta$ accumulation and neuroinflammation, synaptic loss, impaired neuronal function, and ultimately, debilitating cognitive decline [3, 14]. Progressive accumulation and aggregation of $A\beta$ peptides in the brain are thought to be a net result of imbalance between their production and clearance [15]. Moreover, the dramatic increase in cerebral $A\beta$ far precedes the clinical impairment, beginning as early as 20 years prior to symptom manifestation [16]. Therefore, a common view is that any strategy that reduces $A\beta$ levels in the brain, either by inhibiting its production/aggregation or by increasing its clearance, will be advantageous in preventing the development of AD.

$A\beta$ denotes a group of endogenous peptides, typically of 36–43 amino acids. It derives from a larger transmembrane protein, the amyloid precursor protein (APP), in a complex proteolytic process, described extensively elsewhere [17]. The disease-associated (amyloidogenic) aggregation-prone $A\beta$ 1-40 ($A\beta_{40}$) and $A\beta$ 1-42 ($A\beta_{42}$) alloforms are generated through a sequential cleavage of APP by a β -secretase (BACE1) and a γ -secretase transmembrane complex. Mutations within the gene encoding APP and its $A\beta$ coding sequence were found to cause early-onset, autosomal-dominant inherited forms of familial AD (FAD) [18]. Similarly, patients with Down syndrome (trisomy 21) who carry three copies of the *APP* gene develop AD-like $A\beta$ and tau neuropathology, leading to cognitive decline [19]. In addition, inheritance of mutations within the genes encoding for presenilin-1 and -2 (PS1 and PS2), two components of the γ -secretase complex, invariably lead to FAD [20–22] (Table 1). These rare mutations and haplotypes result in either overproduction or increased aggregation of $A\beta$, and

Table 1 Genes associated with Alzheimer's disease

Gene	Type	FREQ ^a	Risk	Locus	Variants	↑ A β prod.	↓ A β clear.	Effects on A β ^b	References
<i>APP</i>	FAD ^c	Rare		21q21.3	Mutations Trisomy 21	✓	–	↑ A $\beta_{42/40}$ ratio; ↑ A β_{42} aggregation	[4, 18, 21, 26–28]
<i>PSEN1</i>	FAD ^c	Rare		14q24.3	Mutations	✓	–	↑ A $\beta_{42/40}$ ratio	[20, 21, 23, 26, 28–31]
<i>PSEN2</i>	FAD ^c	Rare		1q42.13	Mutations	✓	–	↑ A $\beta_{42/40}$ ratio	[21–23, 26, 28, 31]
<i>ABCA7</i>	LOAD	16%		19p13.3	rs3764650 rs3752246 rs4147929	✓	✓	Understudied; ↑ A β secretion; ↓ M Φ /MG A β phagocytosis	[21, 32–39]
<i>ADAM10</i>	LOAD	Rare		15q21.3	Q170H R181G	✓	–	↑ A β production; ↓ α -secretase activity	[40–43]
<i>ACE</i>	LOAD	33–48%		17q23.3	Indel; rs4219 rs1800764 rs4343	–	✓	Controversial; ↓ A β degradation; ↑ A β levels	[43–50]
<i>APOE4^d</i>	LOAD	3% ^e		19q13.2	ϵ 4 Allele ^f ϵ 2 Allele ^g	–	✓	↓ Chaperone-mediated A β processing, clearance	[51–56]
<i>BINI</i>	LOAD	45%		2q14	rs744373 rs7561528	✓	✓	↑ A β production; May ↓ M Φ A β phagocytosis	[33, 34, 57–61]
<i>CD2AP</i>	LOAD	3%		6p12	rs9296559 rs9349407	–	✓	↑ A β plaque burden; ↓ Endosome/lysosome clearance	[33, 37, 57, 62, 63]
<i>CD33</i>	LOAD	30%		19q13.3	rs3865444 ^g rs3826656	–	✓	↓ Mo/MG A β phagocytosis	[33, 34, 64–67]
<i>CLU</i>	LOAD	38%		8p21-p12	rs9331896	–	✓	↓ Chaperone-mediated A β clearance	[32, 68–75]
<i>CR1</i>	LOAD	20%		1q32	rs3818361 rs6656401 rs6701713	–	✓	↓ Immune-mediated A β clearance; ↑ A β_{42} levels	[33, 34, 76–79]
<i>EPHA1</i>	LOAD	34%		7q34	rs11771145 ^g rs11767557 ^g	–	✓	Understudied; ↓ Immune-mediated A β clearance	[32–34, 80–82]
<i>PICALM</i>	LOAD	36%		11q14	rs3851179 ^g rs541458 ^g	✓	✓	↓ Trafficking of A β across BBB; ↑ A β production	[83–89]
<i>SIRT1</i>	LOAD	–		10q21.3	–	✓	✓	↑ MG-dependent A β toxicity; ↓ α -secretase activity	[32, 90–95]
<i>SORL1</i>	LOAD	4%		11q23.2-q24.2	rs12285364 rs2070045 rs2282649	✓	✓	↑ A β production; ↓ APP trafficking to endosomes	[94, 96–101]

Table 1 (continued)

Gene	Type	FREQ ^a	Risk	Locus	Variants	↑ Aβ prod.	↓ Aβ clear.	Effects on Aβ ^b	References
<i>TREM2</i>	LOAD	6%		6p21.1	rs75932628	–	✓	Controversial; ↓ Mo phagocytosis and immune response	[102–108]

ABCA7 ATP-binding cassette, sub-family A (ABC1), member 7, *ACE* angiotensin-converting enzyme, *APOE* apolipoprotein E, *APP* amyloid precursor protein, *BINI* bridging integrator 1, *CD2AP* CD2-associated protein, *CD33* sialic acid-binding immunoglobulin-like lectin 3, *Clear.* clearance, *CLU* clusterin (apolipoprotein J), *CR1* complement component (3b/4b) receptor 1, *EPHA1* EPH receptor A1, *Exp.* gene expression levels in AD, *FAD* early onset familial AD: inherited in an autosomal dominant fashion, *Load* late onset AD, *Mo/MΦ* monocytes/macrophages, *MG* microglia, *PICALM* phosphatidylinositol binding clathrin assembly protein, *Prod.* production, *PSEN1* presenilin 1, *PSEN2* presenilin 2, *SIRT1* sirtuin 1, *SNPs* single nucleotide polymorphisms, *SORL1* sortilin-related receptor 1, *TREM2* triggering receptor expressed on myeloid cells 2

^aApproximate frequency

^bPostulated effects on Aβ and related immune response

^cRare variants identified in LOAD

^dStrongest genetic risk factor for LOAD

^eCarriers of one or two *APOε4* alleles

^fDose-dependent effect of *Apoε4* alleles

^gReduced risk for AD

importantly, in favored generation of the more pathogenic Aβ₄₂ alloforms [4, 23]. These findings strongly tie Aβ to the etiology of AD. Further support for this notion came recently from the identification of a protective *APP* mutation in non-demented Icelanders [24]. The A673T mutation in *APP* (alternatively called A2T mutation in Aβ) was shown to reduce amyloidogenic Aβ production and aggregation, providing protection against age-associated cognitive decline [24, 25].

While FAD represents approximately 5% of all AD cases, the remaining majority of AD cases manifest later in life (typically over 65 years of age), and are termed sporadic or late-onset AD (LOAD). The etiology of LOAD is multifactorial: multiple genetic and environmental factors likely contribute to the development of disease. Strong support for the role of Aβ accumulation in both AD forms came from several clinical studies. While in FAD cases cerebral Aβ increase was explained by Aβ₄₂ overproduction [109], deficient Aβ₄₂ clearance was shown in the brains of LOAD patients [110]. Despite differences in etiology, FAD and LOAD are neuropathologically indistinguishable and present with similar clinical phenotypes [4].

Growing evidence indicates that Aβ exerts its neurotoxic effects in both an alloform- and conformation-dependent manner [7]. Small, soluble oligomeric forms of Aβ₄₂ were shown to be especially neurotoxic [111–113] and more strongly predict cognitive decline than Aβ plaque load [114, 115]. Specifically, Aβ oligomers were shown to impact long-term potentiation, synaptic signaling and plasticity, dendritic morphology, and cognition in rodent models [113, 116–119]. Additionally, Aβ was shown to impair neuronal glucose transport [120] and accumulate within

mitochondria [121], disrupting vital enzymatic activity and increasing free radical production [122]. Aβ fibrils can also induce inflammatory processes by binding to and activating microglia [123, 124] and peripheral monocytes [125–127]. This toxic microenvironment was further associated with impaired calcium regulation and energy metabolism throughout CNS tissues [128]. Beyond amyloid pathology in brain parenchyma, AD patients frequently exhibit cerebral amyloid angiopathy (CAA) along with reduced cerebral blood flow that can further compromise cognitive capacity [129]. This phenomenon was also found in retina microvasculature [13, 130]. In murine models of AD, it was recently found that vascular amyloid deposits hardened blood vessel walls and reduced blood flow [131].

Although the existence of Aβ plaques and NFTs establishes the definitive diagnosis of AD, many researches have challenged the predominant belief that Aβ is central to the development of disease. For example, studies have demonstrated that NFT pathology correlates more strongly than amyloid plaque load with brain atrophy and cognitive decline [132, 133]. In addition, clinical trials targeting cerebral Aβ plaque removal in symptomatic patients have largely failed to provide a clinical benefit and have consequently raised concerns regarding the role of Aβ in the etiology and treatment of AD [134]. Alternative theories of AD pathogenesis have also been postulated. For instance, different groups consider AD to be a combination of multiple disorders of diverse etiology [135], a by-product of normal aging [136, 137], or initiated by faulty immune activation [138]. Others have described AD as a metabolic disorder similar to diabetes, and even coined the term Type 3 Diabetes to highlight their shared molecular and cellular

disturbances, such as insulin resistance, oxidative stress, and glycogen synthase kinase 3 β activation [139]. These data are essential as the field continues to both expand and refine our understanding of AD pathogenesis and explore potential therapeutic avenues. However, this evidence does not preclude A β from playing a principal role in disease. Indeed, several studies have demonstrated that the presence of misfolded A β is sufficient to induce pTau and NFTs *in vitro* and *in vivo* [140–143]. Furthermore, overwhelming data from preclinical animal models have shown that targeting the production, aggregation, or immune-based removal of A β , and especially soluble A β_{42} , preserved synapses and neuronal function as well as prevented cognitive decline [10, 144–146]. Importantly, a recent promising phase Ib human clinical trial, using a monoclonal antibody (aducanumab) to target the removal of both soluble oligomeric and fibrillar A β , has reinvigorated the field of A β -centered AD therapeutics. After 1 year of monthly aducanumab infusions, patients with prodromal or mild AD displayed a reduced cerebral A β plaque load and, by preliminary analyses, exhibited slowing of cognitive decline [147]. Taken together, it is no surprise that A β , in its various forms, remains the focus of AD research and a target for AD prevention and therapy.

In this review, we summarize various cellular and molecular, physiologic mechanisms of A β removal from the brain. Specifically, we cover A β transport across the blood–brain barrier (BBB), glymphatic clearance, cellular uptake, and enzymatic degradation. Large-scale genetic studies have further cemented the connection between A β accumulation, clearance by innate immune cells, and disease risk, and will be the topic of the following section.

Finally, we place a particular emphasis on the growing evidence supporting a key role for microglia, and moreover, monocyte-derived macrophages in the physiological clearance of cerebral A β (see Fig. 1), and we examine their potential as targets for disease-modifying therapies.

Genes related to A β homeostasis and Alzheimer's disease

Historically, the study of AD-related genes pertained to the rare, inheritable and early onset forms of the disease (termed FAD) [4, 22]. These early genetic studies identified FAD as a monogenic disorder resulting from mutations in *APP*, *PS1*, or *PS2* leading to the amyloidogenic processing of APP and overproduction of synaptotoxic A β_{42} (Table 1) [4, 23]. In contrast, the far more common, late-onset AD (LOAD) is a multifactorial disease, with complex and heterogeneous interactions between genetic and environmental factors underlying its development [149, 150]. Importantly, insufficient cerebral A β clearance is thought to drive LOAD pathogenesis [110]. The strongest known susceptibility locus for LOAD encodes apolipoprotein E (ApoE) [51, 151]. Carriers of a single, and moreover, carriers of double *APOE4* alleles have a significantly increased risk of developing AD [51, 151]. Apo ϵ 4 has been implicated in A β trafficking and neurovascular function, with possible additional effects on myeloid cell phenotype and ability to phagocytose A β (discussed further below) [52, 152–154]. Recent genome-wide association studies (GWAS), case-control and family-based studies, whole exome sequencing studies, and meta-analyses of large LOAD patient datasets




Fig. 1 Cerebral A β clearance by peripheral monocyte-derived macrophages. **a** ADtg mice were immunized with dendritic cells (DCs) pulsed with an altered myelin-derived peptide (MOG45D). Brain-resident microglia (MG, Iba1⁺/CD45^{int-low}), and moreover, blood-borne infiltrating Iba1⁺/CD45^{high} macrophages (M Φ , red), are involved in the uptake of cerebral A β (4G8⁺; bright white areas), as shown in the hippocampal region from an immunized ADtg mouse.

Image adopted from Koronyo-Hamaoui et al., J Neurochemistry [148]. **b** Phagocytosis of fibrillar A β_{42} (6E10) and co-localization within CD163⁺CD36^{high} bone marrow-derived macrophages in cultures treated with glatiramer acetate (GA). **c** A GA-immunized ADtg mouse brain exhibiting increased expression of A β -degrading enzyme (MMP-9) by recruited blood-borne M Φ surrounding A β plaques. Microscopic images from Koronyo et al., Brain, [144]

have further identified over 20 novel risk factors with varying effect sizes and frequencies in the population (Table 1) [32–34, 76, 83, 96, 155]. Remarkably, a vast majority of these risk genes are associated with A β processing or trafficking as well as with a wide range of immunological responses, especially those related to myeloid cell-mediated A β clearance [156]. More specifically, LOAD risk genes have been demonstrated to impact inflammation (*APOE*, *INDPP5D*, *CR1*, *TREM2*, *MS4A*), complement activation (*CLU*, *CR1*), the HLA gene complex (*HLA-DRB1*, *HLA-DRB5*), and myeloid cell-mediated A β proteolysis (*ACE*, *CD2AP*) and phagocytosis (*APOE*, *BIN1*, *INPP5D*, *CR1*, *ABCA7*, *TREM2*) [21, 156]. In particular, polymorphisms in the genes *CD33* (sialic acid-binding immunoglobulin-like lectin 3) and *TREM2* (triggering receptor on myeloid cells 2) directly link impaired microglial and macrophage phagocytosis of A β to increased susceptibility to AD. The reported effect size of *TREM2* variants on AD risk has varied in the literature [96, 155]: some investigations estimate an odds ratio of 3–4 (similar to the risk of carrying a single Apoe4 allele), while others show only a small to moderate effect [96, 151, 155, 157]. Nonetheless, *TREM2* has remained in the spotlight for its effects on myelomonocytic cell phenotype and A β phagocytosis, which will be discussed in later sections. It has long been questioned whether AD-associated inflammation and myeloid cell dysfunction drive disease pathogenesis or instead represent a subsequent reaction to the associated neuropathology [123, 158]. Yet, these recent large-scale genetic studies, compiling data from thousands of AD subjects, illustrate unequivocally the principal role of immunological processes in development of AD, and for the first time, provide genetic evidence supporting the significance of the peripheral immune system.

Mechanisms of A β clearance

The key mechanisms of A β clearance were shown to involve either A β removal to the peripheral blood and lymphatic systems or degradation within the CNS tissues. A β reaches the peripheral circulation via chaperone-mediated transport across the blood brain barrier (BBB) [159], perivascular drainage [160], or through the glymphatic system [161, 162]. In the parenchyma, myelomonocytic cells were shown to phagocytose fibrillar A β , and perhaps their soluble oligomeric forms as well. These professional phagocytes, together with astrocytes and neurons, are jointly responsible for degradation and removal of amyloidogenic A β alloforms [123, 163]. Though each system likely contributes to A β clearance to varying extents, their summed effects are essential for A β homeostasis. This implies that perturbations of any singular process may

underlie or predispose to pathologic A β accumulation, and consequently development of AD.

Extracellular enzymatic degradation of A β

Secreted peptidases are critical for the catabolism of A β peptides. These enzymes were reported to have an affinity for specific domains within the A β amino acid sequence and an ability to cleave and convert these peptides to shorter, more benign forms [164–167]. Table 2 describes major A β -degrading enzymes, their substrates, their cellular location and the cell types known to express and secrete them. The following paragraphs describe several A β -degrading enzymes that have been central in AD research.

Angiotensin-converting enzyme (ACE)

ACE is a zinc-dependent peptidase with significant expression by endothelium throughout the body as well as by cortical neurons in the brain [205]. Most well known for transforming angiotensin-I to angiotensin-II and for its role in regulating hemodynamic stability and salt balance, ACE was also shown to degrade A β , and importantly, cleave A β ₄₂ into the less toxic A β ₄₀ alloform [164]. In post-mortem analyses, cortical and perivascular ACE expression was upregulated in the brains of AD patients and correlated with parenchymal plaque load and extent of perivascular amyloid deposition, respectively [206, 207]. Furthermore, lower levels of ACE protein and its activity were associated with lower CSF A β , indicating more prominent amyloid pathology in the parenchyma [44]. It was thus hypothesized that increased ACE activity in CNS tissues is a protective response to increasing amyloid pathology. While this claim is partially supported by both genetic studies in humans and physiologic studies in ADtg mice, there are inconsistencies within the literature. Both case-control studies and several large meta-analyses have identified an insertion within intron 16 of the gene *ACE1* that reduces plasma ACE levels and increases risk for AD [45–47]. However, these findings were not always replicated [208]. Interestingly, AD patients homozygous for the insertion polymorphism had a greater risk of cognitive deterioration and clinical progression than other ACE genotypes [48], suggesting ACE activity may critically modulate the pathophysiology underlying neurodegeneration. Indeed, one long-term study of the ACE-inhibitor (ACE-I) captopril in ADtg mice supports the role of ACE in A β clearance, as both A β plaque load and A β ₄₂ levels were elevated after 11 months of treatment [209]. It is important to note, however, that studies of shorter duration did not report a measurable effect of other ACE-Is on A β pathology [205]. In ADtg mice, ACE overexpression by

Table 2 Amyloid β -degrading enzymes in Alzheimer's disease

Enzyme	Type	Expression	Active site	A β substrate	References
NEP	Type II integral membrane zinc metalloprotease	Membrane-bound; neurons, Mo/M Φ , MG, astrocytes	Ext	sA β _{40,42}	[166, 168–173]
IDE	Zinc metalloprotease	Cytosolic, cell surface, secreted; neurons, Mo/M Φ , MG, astrocytes	Ext and Int	sA β _{40,42}	[165, 174–177]
MMP-2	Matrixin; zinc metalloprotease	Membrane-bound, secreted; endothelial cells, Mo/M Φ , pyramidal neurons, astrocytes	Ext	sA β	[178–182]
MMP-3	Matrixin; Zinc metalloprotease	Secreted; endothelial cells, Mo/M Φ , MG, astrocytes	Ext	sA β	[183, 184]
MMP-9	Matrixin; zinc metalloprotease	Secreted; neurons, MG, astrocytes, Mo/M Φ	Ext	sA β ; fA β ; Mature plaques	[144, 167, 185–190]
ACE	Zinc metalloprotease	Membrane-bound, Secreted; Muscle and endothelial cells, lymphocytes and Mo/M Φ	Ext	sA β _{40,42} ; fA β _{40,42}	[145, 164, 191, 192]
ECE-1	Zinc metalloprotease	Membrane-bound; endothelial cells, neurons, Mo/M Φ , MG, astrocytes	Ext	SynA β ₄₀ ; A β in Ctx and Hip	[193–195]
Cathepsin B	Cysteine protease	Within lysosomes; various cell types	Int	Controversial; APP; A β _{40,42}	[196–201]
Cathepsin D	Aspartic protease	Within lysosomes; various cell types	Int	sA β _{40,42}	[202–204]

ACE angiotensin-converting enzyme, APP amyloid precursor protein, Ctx cortex, ECE-1 endothelin-converting enzyme 1, Ext. extracellular, fA β fibrillar A β , Hip hippocampus, IDE insulin-degrading enzyme, Int. intracellular, Mo/M Φ monocytes/macrophages, MG microglia, MMP-2 matrix metalloproteinase 2, MMP-3 matrix metalloproteinase 3, MMP-9 matrix metalloproteinase 9, NEP neprilysin, oA β oligomeric A β , sA β soluble A β , SynA β synthetic A β

microglia and monocytes/macrophages lead to a dramatic reduction in cerebral A β levels and cognitive decline [145, 191], demonstrating great therapeutic potential discussed further below. Taken together, there is substantial, although inconsistent, evidence implicating ACE in the physiological clearance of A β that merits further investigation.

Insulin-degrading enzyme (IDE)

IDE is a zinc metalloprotease that is capable of degrading soluble A β ₄₀ and A β ₄₂ into non-toxic fragments [165, 174]. Although primarily localized in the cytosol, a small fraction of IDE is secreted by glial cells [175, 176, 185] or expressed on the cell surface of neurons [177], where it serves as a critical enzyme for extracellular A β degradation [165, 210]. Investigations in human and AD rodent models have yielded varying evidence regarding IDE mRNA expression, protein levels, and activity in the AD brain, most likely because the behavior of IDE is highly dependent on age [211–213], brain region [211–213], disease severity [212, 213], and APOE status [214]. In general, it seems IDE levels and activities are upregulated in response to A β exposure, with the exception of *ApoE4/4* carriers, who exhibit reduced IDE expression.

Matrix metalloproteinase-9 (MMP-9)

MMP-9 is a secreted enzyme and member of the zinc metalloprotease (MMP) family. In general, MMPs are responsible for the degradation and maintenance of the extracellular matrix. MMP-9 has been shown to degrade compact plaques [186, 187] as well as soluble A β ₄₂ and A β ₄₀ [167]. In the CNS, MMP-9 is expressed by neurons [188], microglia [189], astrocytes [190], and infiltrating Iba⁺/CD45^{hi} monocytes (Fig. 1C) [144, 148]. MMP-9 has also been shown to act as an α -secretase, favoring non-amyloidogenic processing of APP and the production of sAPP α [215]. In addition to its efficient degradation of A β , MMP-9 was shown to be involved in both TNF α -mediated pro-inflammatory and anti-inflammatory signaling in activated macrophages and microglia [216, 217]. Elevated levels of MMP-9 have been correlated with BBB breakdown, demyelination, and cell death in other CNS disorders like multiple sclerosis [218] and spinal cord injury [219]. These effects should be considered when modulating MMP-9 activity *in vivo*.

Nepriylisin (NEP)

NEP is a type II integral membrane zinc metalloprotein with the bulk of its structure, including the active site, facing the extracellular space. NEP is expressed throughout the brain, predominantly on pre- and post-synaptic neuronal membranes [168, 169], and by microglia [170] and astrocytes [171]. NEP is considered the most potent A β -degrading enzyme [220, 221], preferentially cleaving oligomeric A β_{42} and A β_{40} [166, 172] but not fibrillar forms. NEP expression and activity has been shown to decline with age and disease in post-mortem human AD brain tissue [222], which may contribute to A β accumulation. Modeling this reduction by dampening NEP expression [223, 224] or activity [225] in ADtg mice resulted in elevated A β pathology and cognitive deficits. Conversely, the beneficial effects of NEP overexpression speak to the therapeutic potential of targeting neprilysin activity, discussed further below [146, 172].

Enzymatic degradation by innate immune cells

NEP, IDE, ACE and MMP-9 are A β -degrading enzymes expressed by innate immune cells and represent a crucial pathway by which these cells may eradicate pathogenic A β (Table 2). Expression of NEP, IDE, and MMP-9 was shown to decline in microglia of aged APP/PS1 mice, which may contribute to their functional impairment in later stages of AD [170]. This altered microglial phenotype was contingent on the presence of A β , as microglia from age-matched controls did not exhibit reduced enzyme expression. Microglial expression of NEP and IDE were also shown to be highly inducible *in vitro* and correlated with enhanced clearance of soluble A β_{42} [226].

For proteolytic processing of A β by monocyte-derived macrophages, the expression of MMP-9 appears to be especially important. APP_{SWE}/PS1 $_{\Delta E9}$ mice infused with CD115⁺ monocytes or immunized with the altered myelin-derived antigens, such as glatiramer acetate (GA) or myelin oligodendrocyte glycoprotein-derived peptide (MOG45D) displayed increased accumulation of MMP-9-secreting macrophages surrounding A β plaques (Fig. 1c), along with a marked reduction in A β neuropathology and cognitive impairment [144, 148]. GA stimulation of bone marrow-derived macrophages *in vitro* also dramatically induced MMP-9 expression [144]. Additionally, peripheral macrophages cultured on top of plaque-bearing brain sections of PDAPP mice cleared A β , in part, by upregulated expression of MMP-9 [185]. Interestingly, macrophages expressed MMP-9 in an ApoE-dependent manner. Apo ϵ 4 significantly dampened MMP-9 expression, suggesting an additional mechanism by which Apo ϵ 4 disrupts A β clearance [185].

Furthermore, ACE has a demonstrated ability to modulate the behavior of innate immune cells in ADtg murine models [191, 227]. In other disease models, targeted overexpression of ACE to myelomonocytic cells enhances their immune function, including their ability to clear cellular debris and promote tissue repair. Targeted ACE overexpression to myelomonocytes (ACE10/10 model) introduced to APP_{SWE}/PS1 $_{\Delta E9}$ transgenic mice resulted in increased infiltration of monocyte-derived macrophages that were tightly associated with A β plaques and displayed increased ability to phagocytose A β [145]. The net result was reduced soluble and insoluble A β levels, attenuated neuroinflammation, and improved cognitive performance. In contrast, inhibition of ACE catalytic domains in ACE10/10-ADtg mice exacerbated cerebral A β pathology [145]. Overall, the beneficial outcomes of ACE overexpression in myelomonocytes were most likely due to the summed effects of the enhanced immune response and proteolytic capacity endowed by ACE expression.

Intracellular degradation systems

Another important mechanism of A β catabolism is undertaken within cells that either absorb or engulf A β forms. Three such critical pathways—autophagy, endosomal/lysosomal degradation, and the ubiquitin–proteasome system (UPS)—prevent intracellular protein aggregation, and are thus instrumental in protecting against the neurotoxicity of cytosolic A β accumulation. In AD brains, however, these systems are considerably compromised [228–231]. Degradation targets for both the UPS and autophagy originate from the cytosol, although their identities differ between the two processes. Autophagy typically facilitates clearance of larger protein aggregates and damaged organelles, while the UPS degrades misfolded or damaged proteins. Furthermore, the UPS is more highly regulated than autophagy, requiring poly-ubiquitination of the target protein for its degradation. The lysosome, too, facilitates intracellular protein degradation, though the origin of these proteins may be either cytosolic or extracellular. Because the lysosome is a final common pathway for several systems, including autophagy, it is discussed separately below.

Lysosomal degradation

The lysosome is the final destination for both autophagic vacuoles and the endosomes formed by receptor-mediated endocytosis. The latter process occurs in neurons and glia through a distinct set of molecular chaperones, discussed in greater detail in the following sections. Each lysosome contains a cocktail of hydrolytic enzymes capable of degrading A β ; however, the hydrolytic machinery is often

overwhelmed in AD [228, 232–234]. As A β load exceeds the degradation capacity of the lysosome, aggregates may grow larger or leak into the cytosol [228, 232–234]. Aging [235] and the presence of Apo ϵ 4 [234, 236] particularly promote lysosomal instability. Intracellular A β negatively impacts multiple cellular and organelle functions, including proteasome inhibition, mitochondrial abnormalities, tau hyperphosphorylation, and presumably, the seeding of amyloid plaques following cell death [121, 237, 238].

Myeloid cells in particular may suffer AD-associated deficits in endosomal-lysosomal trafficking and A β processing. Microglia isolated from plaque-bearing sections of human AD tissue indicated that A β fibrils were located in the endoplasmic reticulum and deep invaginations of the cell membrane, instead of within endosomes or lysosomes [239]. Even non-diseased microglia cultured with fibrillar A β ₄₂ showed incomplete intracellular degradation, with non-degraded fibrils remaining in phagosomes for up to 20 days [239, 240]. This impairment was not seen in peripheral macrophage cultures under the same conditions. In fact, after 3 days of incubation with fibrillar A β , less than 30% of A β was retained in peritoneal macrophages, indicating successful degradation, while 80% remained associated with microglia [241]. One possible explanation for deficient microglial clearance is insufficient activity of lysosomal A β -degrading enzymes. In support of this notion, incubating microglia with mannose-6-phosphate tagged lysosomal enzymes rescued the clearance impairment. Mannose-6-phosphate typically targets hydrolytic enzymes to the lysosome from the Golgi apparatus, and this modification has been used to deliver extracellular enzymes to the lysosome in experimental conditions [242].

While healthy peripheral macrophages appear better equipped to degrade fibrillar A β than resident microglia, monocytes in AD patients exhibit lysosomal dysfunction [125, 229]. Specifically, more undigested A β molecules exist within monocytes isolated from AD patients compared to those from healthy age-matched controls, a deficit partially attributable to reduced expression and activity of cathepsin D and other major lysosomal enzymes [229, 243]. Upregulation of miR-128 was shown to target the transcripts of these enzymes and mediate their suppression. The discrepancy in lysosomal degradation capacity between microglia and infiltrating macrophages highlights their non-redundant roles in restricting A β pathology and as targets for future intervention.

Autophagy-mediated degradation

Three types of autophagy exist: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA). While both macroautophagy and CMA dysfunction are implicated in AD [244, 245], the former is considered to

be the predominant process, and will be referred to simply as “autophagy” throughout [245]. The mechanism of autophagy-mediated clearance involves isolation of cytoplasmic contents by a double-membrane vesicle called an autophagosome or autophagic vacuole (AV). Subsequent lysosomal fusion facilitates degradation of the AV and its contents [246], which may include A β and APP [247, 248]. In both AD patients and ADtg models, autophagy is markedly impaired, evidenced by the large accumulation of unprocessed, A β -rich AVs in dystrophic neurites [249, 250]. Indeed, deficits in the autophagy-lysosomal pathway occur early in the disease process, perhaps even preceding A β accumulation [230, 251]. Reduced expression of key autophagic proteins (beclin-1 and autophagy proteins 5 and 7) likely contribute to autophagic dysfunction, A β accumulation, and neuronal cell death [248, 252–254]. Furthermore, perturbations in signaling through the mammalian target of rapamycin (mTOR) pathway, the key regulator of autophagic activity, may also contribute to its impairment in AD. Under nutrient-rich conditions, heightened mTOR signaling suppresses autophagy by phosphorylating proteins necessary for AV formation and elongation [255]. Other pathologic conditions, such as cellular starvation, oxidative stress, organelle damage, and protein aggregation, inactivate mTOR and promote autophagy as a protective response [256, 257]. In the brains of AD patients, however, mTOR signaling was shown to be inappropriately active given the toxic environment [258]. Inhibition of the mTOR pathway has thus emerged as an attractive target for therapeutic intervention, with a demonstrated benefit on A β levels and cognition in murine models of AD [259].

Ubiquitin–proteasome system (UPS)

The UPS is a highly regulated degradation process for cytosolic short-lived and misfolded proteins. As such, it is an important protective mechanism against neurotoxic protein aggregates. Briefly, specific proteins are polyubiquitinated by a series of ligases (E1, E2, and E3) for recognition and degradation by the 26S proteasome complex. Whether UPS dysfunction is a cause or consequence of AD-related degeneration remains unknown. In favor of the former, both ubiquitin conjugation and proteasome activity decline with age and in AD tissue [231, 260, 261]. Areas with reduced proteasome function overlap with those greatly impacted by AD: the hippocampus, nearby limbic structures, and the inferior parietal lobe [231]. Diminished activity of the 26S complex promotes A β deposition and perhaps its production as well through increased maturation and trafficking of APP [262, 263]. Taken together, this data could imply that declining proteasome function in aging and disease leaves the brain susceptible to A β aggregation. Nonetheless, multiple reports have demonstrated that A β accumulation, in

fact, inhibits proteasome activity, possibly by directly binding to the 20S catalytic subunit [238, 263]. A β accumulation may then contribute to proteasome dysfunction rather than result from it, although these interactions need not be mutually exclusive.

A β clearance mediated by extracellular chaperones

Removal of A β into the peripheral circulation is thought to facilitate the majority of physiologic A β clearance [264]. Transport across the BBB requires a specialized transport system of molecular chaperones. Specifically, members of the LDL receptor (LDLR) family, such as the low-density lipoprotein-related protein 1 (LRP-1) and ATP-binding cassette (ABC) transporters, are primary receptors for A β efflux [264]. LRP-1-mediated transport requires the assistance of additional adaptor proteins, and this system in total will be the focus of this section. Transporters that mediate A β influx into the brain parenchyma, such as the receptor for advanced glycation endproducts (RAGE), will not be discussed.

Lipoprotein-related protein 1 (LRP-1)

Located on the abluminal surface of brain endothelial cells, LRP-1 binds either ApoE-A β complexes or A β alone [53, 265], subsequently stimulating endocytosis of either species. Notably, once A β is contained within endothelial cells, the luminal transport protein ABCB1 facilitates the removal of A β species into the vascular lumen [266]. Blocking LRP-1 expression in healthy, non-ADtg mice led to impaired A β clearance across the BBB, and consequently, greater A β deposition and cognitive deficits [267]. This study may recapitulate some of the consequences of declining LRP-1 expression reported in ADtg mice, AD patients, and aging adults [159, 265, 268]. Additionally, LRP-1 is expressed on neurons, astrocytes, and microglia, facilitating cellular A β uptake and lysosomal degradation within these cells [269–271].

Phosphatidylinositol binding clathrin assembly protein (PICALM)

PICALM is expressed on endothelial cells, and to a lesser extent, on neurons [272]. PICALM primarily functions as an adapter protein for the transcytosis of the A β -LRP-1 complex across the BBB. In addition to its role in A β clearance, recent reports show that single nucleotide polymorphisms (SNPs) in the upstream coding region for PICALM are major risk factors for AD [83, 273]. This may indicate that appropriate PICALM function is protective. In support

of this, PICALM levels in cortical microvessels of subjects with advanced AD were half the levels measured in age-matched controls. Subjects with the lowest PICALM levels displayed the greatest A β burden and cognitive impairment [274].

Apolipoprotein E (ApoE)

Under physiologic conditions, ApoE is a carrier protein that maintains cholesterol and phospholipid homeostasis [275]. Major ApoE receptors include LDLR, LRP-1, the very low-density lipoprotein receptor (VLDLR), and ApoE receptor 2 (ApoER2) [276, 277]. However, the exact role of ApoE in AD pathogenesis remains elusive despite mounting evidence from genetic, physiologic, and clinical studies that unequivocally supports the carrier protein's importance [51, 52, 151, 278–281]. *In vitro* studies have helped to elucidate the role of ApoE, demonstrating that it binds A β directly under certain conditions [282]. It is thought that the resulting ApoE-A β complexes bind to and are internalized by LRP-1 for delivery to the vasculature and removal from the brain [53, 68]. Supporting this amyloid-clearing role for ApoE, a recent study revealed that ApoE levels inversely correlated with cerebral A β load in non-demented healthy controls [283]. In contrast, however, ApoE was shown to compete with fibrillar or soluble A β for uptake and degradation by microglia and astrocytes, respectively [54, 284]. Taken together, the literature suggests distinct mechanisms by which ApoE enhances and hinders A β clearance. The effect likely depends on the specific A β conformation, the ApoE isoform and its lipidation state, as well as the relative ApoE receptor expression on the target cell [278].

Three isoforms of ApoE exist in humans: Apo ϵ 2, Apo ϵ 3, and Apo ϵ 4 [279]. Evidence suggests that the *APOE2* allele may be protective against AD [151]; conversely, carrying one, or to a greater extent, two *APOE4* alleles significantly increases the risk of developing AD and reduces the age of onset [51, 151, 282]. Furthermore, the *APOE4/4* genotype is associated with accelerated and more pronounced cerebral amyloid pathology and CSF abnormalities [285]. Several pathogenic mechanisms may explain this increased risk associated with Apo ϵ 4. First, the rate of vascular A β clearance is diminished in those expressing Apo ϵ 4 compared to other isoforms [52, 53, 152], perhaps due to its reduced affinity for A β [286]. Additionally, Apo ϵ 4 can redirect the ApoE-A β complex to a different receptor, VLDLR, which has slower internalization kinetics than other LDLRs [53]. The net result is reduced internalization of A β by LRP-1, and ultimately reduced A β clearance [280, 281, 287]. Apo ϵ 4 may also promote damage to the BBB by upregulation of pro-inflammatory signaling through cyclophilin A [153]. In non-demented murine models, Apo ϵ 4 led to reduced cerebral blood flow and microvascular

length, while also increasing BBB permeability [153]. A compromised BBB can reduce vascular A β clearance and predispose to further injury through leakage of toxic blood proteins [153, 288]. These destructive outcomes were not observed in mice expressing Apo ϵ 2 or Apo ϵ 3 [153, 289].

Apo ϵ 4 may hinder other important mechanisms of A β clearance, namely, intracellular catabolism by neurons and innate immune cells. Specifically, Apo ϵ 4 may interfere with these processes by inducing lysosomal leakage or by impeding myeloid cell-mediated clearance [185, 234, 236]. Though ApoE normally has an anti-inflammatory effect, this trait is markedly dampened by expression of Apo ϵ 4 on innate immune cells [154]. Crossing *APOE4*-targeted replacement mice with the 5XFAD ADtg model greatly increased microgliosis and astrogliosis surrounding A β plaques [290]. Similarly, in cell cultures of microglia and astrocytes isolated from these Apo ϵ 4-expressing mice, more pro-inflammatory cytokines were released from these cells in response to soluble oligomeric A β than from those expressing Apo ϵ 3 [154]. Furthermore, peripheral macrophages expressing Apo ϵ 4 exhibited a diminished capacity to phagocytose and clear A β when cultured on top of plaque-bearing brain sections of PDAPP mice [185]. It remains unclear whether Apo ϵ 4 influences AD predominantly through gain of toxic function, loss of protective function (i.e. vascular/immune cell dysfunction), or both. Further investigation is required to reveal the exact role of ApoE and its isoforms in AD, and the possible therapeutic potential of its manipulation.

Glymphatic clearance

The glymphatic system is a pathway of brain-wide waste clearance for small proteins and metabolites. In this pathway, CSF enters the periarterial space and, driven by arterial pulsations, enters the brain parenchyma to exchange with the interstitial fluid (ISF). Bulk flow of CSF/ISF, containing extracellular molecules such as A β , are then driven to perivenous spaces for recirculation in the CSF or clearance to peripheral lymphatics [161, 162]. Glymphatic activity is greatest during sleep, with A β clearance rates doubling those observed in periods of wakefulness [291]. The glymphatic system was named, in part, for acting as a surrogate to CNS lymphatic drainage, a system the brain traditionally lacked. However, a recent, seminal study has identified meningeal lymphatic vessels for the first time [292, 293]. This groundbreaking discovery calls for a re-evaluation of current notions of the neuroimmune connection, and raises exciting potential explanations of the pathophysiology of A β accumulation and defective clearance in some cases.

Water channels known as aquaporin 4 (AQP4) are the key elements in CSF-ISF exchange, and thus clearance through the glymphatic pathway. AQP4 is located on astrocytic end feet and encircles the vasculature. Mice lacking astrocytic AQP4 showed reduced CSF influx by ~70% and decreased interstitial A β clearance by ~55–65% [161, 162]. Advanced age also reduced glymphatic clearance rates in murine models, perhaps due to an age-dependent loss of AQP4 polarization [294]. Interstitial solutes may also be cleared directly into the CSF compartment through periarterial pathways flowing opposite to the glymphatic system. These two pathways may not be mutually exclusive; they might be two components of the same system, or their activities may vary in space and time throughout the CNS [264].

Myeloid cell-mediated phagocytosis

A growing body of evidence supports the emerging concept that activated inflammatory cells, mainly brain-resident microglia and infiltrating blood-borne monocyte-derived macrophages, are critical for the physiological clearance of A β [148, 295–298]. Microglia are tightly associated with A β deposits and senile plaques, and early studies have documented their involvement in cellular A β uptake [299, 300]. However, these investigations were lacking the capacity to distinguish activated microglia from blood-borne macrophages due to their similar immunophenotype and function. Recruited macrophages were thus inappropriately characterized as part of the microglial pool, and confusion ensued over their unique behavior [296, 301].

Today's newer methodologies delineate subtle differences in marker expression, allowing for a more accurate categorization and attribution of function to these cell populations. For example, standard CD11b (MAC1), isolectin B4 (IB4), F4/80, or ionized calcium binding adapter molecule 1 (Iba1) markers in the brain are indistinguishably expressed by both infiltrating monocytes and resident microglia [302, 303]. Yet, the combination of one of these myelomonocytic markers with differential expression levels of CD45 [304, 305], P2RY12 [306], or Ly6C [303] can help differentiate these cell types (Fig. 1a, c). Other approaches may involve fluorescent labeling of peripheral innate immune cells (i.e. green or red fluorescent protein-labeled, GFP or RFP, respectively) or introducing genetic modifications, such as targeted NEP- or ACE overexpression in monocytic cells [145, 146, 191].

Other key developmental and functional differences between microglia and macrophages help distinguish these unique cell types. Microglia originate from hematopoietic stem cells of the yolk sac [307], while infiltrating monocyte-derived macrophages originate from bone marrow

hematopoietic myelomonocytes [308]. In early post-natal life, microglia participate in synaptic pruning [309]. Later on, they are critical for maintaining CNS homeostasis, regulating immune surveillance, and responding to pathologic changes such as A β aggregation [310]. Less is known about CNS monocyte interactions under physiological conditions [311]. A comprehensive comparison of these two cell types is beyond the scope of this manuscript; however, detailed reviews on their unique embryology, development, and immune responses can be found elsewhere [303, 307, 308].

Heterogeneous populations of these immune cells exist in the brain, especially in the diseased state. Their demonstrated clearance capacity varies given the experimental paradigm and the phase of disease studied. Table 3 provides a summary of research on monocytes/macrophages in human AD subjects, while Table 4 briefly describes similar data in rodent models. The discussion that follows describes the phagocytic process mediated by microglia and monocyte-derived macrophages and the conditions in which they differ. When evaluating this data, it is important

to keep in mind the difficulties involved in assessing peripheral monocytes and microglia as distinct cell types. Therefore, we cannot rule out the possibility that some investigations illustrating a role for microglia may also include effects of infiltrating monocytes.

Microglia-mediated phagocytosis

Microglia aid in the normal development, function, and repair of the CNS. In response to injury or other pathological conditions, microglial processes and cell bodies migrate to lesion sites and initiate an immune response to contain and resolve particular insults [123, 124, 299]. Activated microglia are closely associated with senile plaques in both human and ADtg models. While microglia are capable of clearing A β *in vitro* [241, 300, 332–334], their *in vivo* clearance capacity has been questioned [335–337]. Successful A β internalization by microglia has been documented in some cases [338, 339], while others report incomplete processing [239, 240, 335–337]. In support of

Table 3 Alzheimer's disease-related impairments in human myeloid cells

Study type	Study design	Altered protein/gene	Mo phenotype and A β clearance	References
HC Mo and MG	Pulse-chase analysis of cytokine impact on A β degradation	\uparrow IFN- γ , TNF- α \uparrow IL-4, IL-10, and TGF- β 1	\downarrow A β degradation with pro-inflammatory cytokines; \downarrow IDE \uparrow A β degradation with anti-inflammatory and regulatory cytokines	[312]
AD Mo	rt-PCR and flow cytometry analysis of CD33 expression	\downarrow CD33 mRNA	\downarrow CD33 ⁺ Mo in AD Patients; Positive correlation between number of CD33 ⁺ Mo and MMSE scores	[313]
	Inflammatory profile; Mo analysis	\uparrow HLA-DR and CD16 \uparrow MCP-1 plasma levels \downarrow CCR2 expression	\downarrow Cerebral recruitment of Mo; \uparrow Granularity by SSC	[314]
	Compared Mo from AD patients to HC	\uparrow Inflammatory profile expressing CCR2, IL-6, IL-23, TLRs \downarrow MGAT3 and TLR \downarrow Cathepsin B, D, S \downarrow Activity of β -Galactosidase, α -Manosidase β -Hexosaminidase	\uparrow Apoptosis; \downarrow A β phagocytosis by Mo; Impaired phenotype	[125, 127, 229, 243, 315]
AD vs. MCI Mo	Histone acetylation; cytokine release; susceptibility to cell damage	\uparrow Production of MIP2 and TNF- α \downarrow Acetylation of H4K12 compared to MCI	\uparrow Mo cell damage susceptibility in AD vs. MCI	[316]
AD peripheral blood	Microarray assessment of gene expression in blood; blood count	Multiple early changes in gene expression >700 altered in blood from MCI, AD vs. HC	\uparrow Mo number in AD vs. HC; \uparrow genes encoding cell adhesion molecules and other immune-related genes	[317]

CCR2 C-C chemokine receptor type 2, *CD33* Sialic acid-binding immunoglobulin-like lectin 3, *H4K12* histone H4 at lysine 12, *HC* healthy control, *HLA-DR* human Leukocyte Antigen–antigen D Related (MHC class II surface receptor), *IDE* insulin degrading enzyme, *IFN- γ* interferon- γ , *IL-4* interleukin-4, *IL-6* interleukin-6, *IL-10* interleukin-10, *IL-23* interleukin-23, *MCI* mild cognitive impairment, *MCP-1* monocyte chemoattractant protein-1, *MG* microglia, *MGAT3* beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase, *MIP2* macrophage inflammatory protein 2, *MMSE* mini-mental state examination (Folstein test)—questionnaire used extensively in clinical and research settings to measure cognitive impairment, *Mo/M Φ* monocytes/macrophages, *rt-PCR* reverse transcription polymerase chain reaction, *SSC* side light-scatter characteristics (flow cytometry—measure of granularity and differentiation), *TGF- β 1* transforming growth factor- β 1, *TLRs* toll-like receptors, *TNF- α* tumor necrosis factor- α

Table 4 Studies in rodent models of Alzheimer's disease implicating a role for peripheral myeloid cells in cerebral A β clearance

Study Type	Study design	Mo infiltration ^a	A β phagocytosis by Mo	A β levels	Neuroinflammation	Cognition	References
BM Transplantation	GFP-labeled BM cells in ADtg	✓	✓	↓	–	–	[144, 146, 295, 318, 319]
Blood Enrichment of BM-derived Mo	Treated ADtg mice with M-CSF or infusion of CD115 ⁺ GFP-labeled Mo	✓	✓	↓	↓	↑	[144, 146, 320, 321]
Immune Modulation	MOG45D-DC or GA immunization of ADtg	✓	✓	↓	↓	↑	[144, 148, 297]
Genetic Manipulation in Mo/MG	Infusion of GFP-labeled CD11b ⁺ WT- or NEP-overexpressing Mo from healthy murine BM donors in ADtg	✓	–	↓	–	–	[146]
	Targeted ACE overexpression of CD115 ⁺ Mo/MG in ADtg	✓	✓	↓	↓	↑	[145, 191, 227]
	Targeted blockade of TGF- β and Smad2/3 signaling in innate immune cells of ADtg	✓	✓	↓	↓	–	[322]
	Upregulation of TREM2 in ADtg	–	✓	↓	↓	↑	[323]
	TREM2 knockout in ADtg and stroke models	X (CD45 ^{hi} Ly6C ⁺)	✓	↓	↓	–	[324, 325]
	SCARA1 upregulation	–	✓	↓	–	–	[326]
	Cultured WT macrophages on plaque-bearing sections of murine models	–	✓ (APOE ^b)	↓	–	–	[185]
	CCL2 (MCP-1) and APP expression effects on A β clearance in primary BM-derived macrophages	–	✓	↓	–	–	[327]
	Ablation	Depletion of CD11c ⁺ BM-derived myeloid cell or perivascular M Φ in ADtg	X	X	↑	–	–
Inhibited Mo Infiltration	CCR2-deficient Mo in ADtg	X	X	↑	–	↓	[298, 330, 331]

A β amyloid-beta protein, ACE angiotensin-converting enzyme, ADtg transgenic murine models of Alzheimer's disease, APOE apolipoprotein E, APP amyloid-precursor protein, BM bone marrow, CCL2 C-C chemokine ligand 2, alternatively named monocyte chemoattractant protein 1 (MCP-1), CCR2 C-C chemokine receptor type 2, GA glatiramer acetate, GFP green fluorescent protein, M-CSF macrophage colony-stimulating factor, M Φ macrophages, MG microglia, Mo monocytes, MOG45D-DC dendritic cells loaded with altered myelin oligodendrocyte glycoprotein-derived peptide (MOG45D; a weak agonist and a non-encephalitogenic variant of MOG_(35–55) peptide), NEP neprilysin, SCARA1 class A1 scavenger receptor, TGF- β transforming growth factor- β , WT wild type

^aIncreased Mo infiltration per A β plaques

^bAPOE-dependent effect

the latter, depletion of microglia in three different ADtg mouse models had no effect on fibrillar or soluble A β accumulation, indicating that microglia are not chiefly responsible for A β clearance in these models [335, 336]. Moreover, aging and toxic conditions in the AD brain render microglia chronically activated. This further reduces their phagocytic capacity and causes a prolonged neuroinflammatory response, including production of reactive oxygen species (ROS), cytokines [e.g. IL-1 β , IL-6, TNF α , and transforming growth factor β (TGF- β)] and chemokines

[e.g. macrophage inflammatory proteins (MIPs), monocyte chemoattractant protein 1 (MCP-1), and C-C chemokine receptor types 3 and 5 (CCL3 and CCL5)] [340–342]. Elevated levels of these mediators have potent neurotoxic effects [343, 344] and correlate with increased A β pathology in certain brain regions of human AD patients and transgenic murine (APP/PS1) models [345]. Additionally, recent reports showed that microglia continue to participate in synaptic remodeling in aged mice [346], and can exacerbate synaptic dysfunction by modifying dendritic spine

density and inappropriately engulfing endangered neurons [310, 347]. The aberrant microglial-mediated engulfment of dysfunctional synapses in ADtg models was mediated by components of the complement cascade (i.e. C1q, C3, CR3). Considering the recent genetic data linking certain SNPs in CR1 to the development of AD (Table 1), this work provides further support for the role of the immune system in AD.

Although this indicates a detrimental role for microglia in the AD brain, plaque-associated microglia have been shown to degrade scar tissue proteins with secreted proteases, clear cellular debris, and recruit the adaptive arm of the immune system to stimulate or regulate effective local immune responses [148, 348]. A recent investigation using *in vivo* two photon imaging also demonstrated that early on, microglia form a protective barrier around developing plaques, preventing accumulation of A β ₄₂ protofibrils and associated local neuritic damage [349]. Remarkably, a recent study demonstrated that stimulating hippocampal interneurons at frequencies consistent with gamma oscillations alters microglial phenotype and behavior in the 5XFAD model [350]. A 1-hour delivery of 40 Hz stimulation lowered global A β levels and modified microglial gene expression so that they more efficiently engulfed A β . Based on the available evidence, microglia cannot be labeled as either neuroprotective or neurotoxic. Instead, microglia co-exist in a range of functional states: ramified-resting under physiological conditions, classically and alternatively activated in response to injury, or dystrophic and neurotoxic in aging and chronic inflammation. These phenotypes are highly sensitive to the changes in CNS composition that accompany senescence and the neurodegeneration seen in AD [351]. Current research posits that in early stages of disease, healthy microglia comprise the first line of defense in restricting A β pathology, effectively clearing fibrillar and soluble A β through phagocytosis and proteolytic processing [123]. However, aged and diseased microglia in the AD brain have a markedly reduced capacity to do so [335, 337, 339, 349]. Taken together, it is not surprising that microglia have become candidates for potential disease-modifying therapies.

Monocyte/macrophage-mediated A β phagocytosis

Like microglia, monocyte-derived macrophages are professional phagocytes that support normal tissue function. However, microglial senescence in AD suggests that monocytes may have unique, complementary functions in the disease state, although this conclusion is highly controversial [303, 352–355]. Supporting evidence from genetic and physiological studies of human peripheral blood monocytes (PBMCs) highlights the importance of healthy, functional monocytes in mitigating disease (see summary of studies

in Table 3). PBMCs isolated from AD patients exhibit poor differentiation, impaired phagocytosis, and increased pro-inflammatory cytokine production in response to soluble A β [125, 127, 229, 243, 315, 356] (Table 3). Further, rare variants of *CD33* and *TREM2*, two genes negatively impacting the phagocytic and A β clearance capacity of monocytes, confer a greater risk of developing AD (Table 1) [33, 34, 64, 96, 155]. It remains to be elucidated whether the altered monocyte phenotype is a cause or consequence of disease.

Receptor-mediated A β phagocytosis: molecular machinery

Despite key differences highlighted previously, microglia and monocyte-derived macrophages do overlap in terms of phagocytic receptor expression and behavior [296, 301]. An extensive body of work describes under which conditions and by which mechanisms these cells are capable of engulfing distinct A β species. For example, microglia have been shown to phagocytose fibrillar A β ₄₀ and A β ₄₂ under *in vitro* [239, 299, 300, 334, 357], *in vivo* [358, 359], and *ex vivo* experimental conditions [357, 360]. However, the mechanism underlying soluble A β uptake is less clear. Some argue that microglia phagocytose soluble A β ₄₂ as they do fibrillar forms [332, 361], while others suggest uptake occurs through fluid-phase macropinocytosis [333]. These two processes may not be mutually exclusive; more precise methods of isolating distinct soluble oligomeric forms may reveal assembly dependent interactions with microglia. Similarly, studies using PBMCs isolated from healthy patients have demonstrated the ability of monocytes to effectively bind [356] and engulf soluble and fibrillar A β ₄₂ [125, 185, 315]. The following sections describe the major phagocytic receptors engaged in myeloid cell-mediated physiologic clearance of A β . Whenever possible, the discussion delineates between uptake of soluble oligomeric A β ₄₂, fibrillar A β ₄₂, and other conformations or alloforms. This distinction is particularly relevant given the varying toxicities of different A β species.

Toll-like receptors (TLRs)

TLRs are a family of pattern recognition receptors with distinct functions in the innate immune response. TLR2 and TLR4, in particular, were shown to be indirectly involved in A β phagocytosis through the formation of a receptor complex with CD14 and the subsequent activation of microglia and monocytes. Inhibiting or deleting any component of the CD14-TLR receptor complex in human monocytes or murine microglia diminished the production

of pro-inflammatory cytokines and phagocytosis of fibrillar A β_{42} [362, 363].

Macrophage scavenger receptor 1 (SCARA1)

SCARA1 (alternatively named MSR-1, CD204, type-A1 scavenger receptor, and SR-A) is one of the principal receptors involved in A β uptake by immune cells. It is expressed on human and rodent macrophages [364], microglia [299, 332], and human monocytes [365]. SCARA1 can bind both soluble and fibrillar A β_{42} *in vitro* [326, 332, 365] and facilitate its subsequent uptake. Lack of functional SCARA1 in murine microglia and monocytes reduced A β_{42} uptake by a range of 50%–65% in several experimental preparations [326, 366]. Glatiramer acetate (GA), an altered myelin-derived antigen with demonstrated immunomodulatory benefits in ADtg mice [9, 144, 148, 348, 367], was shown to upregulate surface expression of SCARA1 on monocyte-derived macrophages and to increase A β uptake by this cell population [144]. Immunization with the FDA approved drug, GA, is an intriguing therapeutic strategy and will be discussed further below.

The importance of SCARA1 function in A β clearance has also been established *in vivo*. SCARA1-deficient APP_{SWE}/PS1 $_{\Delta E9}$ transgenic mice exhibited increased mortality and a significant elevation in surface area fraction stained for A β compared to control ADtg mice [326]. Increased microglial expression of SCARA1 around A β plaques has been demonstrated in multiple ADtg models [368, 369] as well as in human AD brains [370]. SCARA1 expression on CNS phagocytes appears to have a neuroprotective role in restricting toxic forms of A β and mitigating disease progression.

CD36

CD36 is a type B scavenger receptor expressed on the cell surface of monocytes, macrophages, astrocytes, and neurons [371]. CD36 has been shown to mediate phagocytosis of fibrillar A β_{42} through interactions with two distinct receptor complexes acting as a functional unit [334, 368, 371]. CD36-deficiency prevents microglial accumulation in response to stereotaxic intracerebral injections of fibrillar A β [372], and antagonists of CD36 effectively block phagocytosis of fibrillar A β_{42} in microglia cell lines [334]. Like SCARA1, expression of CD36 is substantially increased in monocyte-derived macrophages in response to GA stimulation, which may contribute to their superior A β clearance ability compared to untreated macrophages [144] (Fig. 1b; Table 4). CD36 was also shown to bind soluble A β_{42} directly [361, 373], although it may play a redundant

role in soluble A β_{42} clearance [326]. Specific knockdown or inhibition of CD36 demonstrated a sustained ability of microglia to phagocytose soluble A β_{42} with continued expression of other scavenger receptors [332, 361].

CD36 adequately demonstrates the dichotomous role of microglia in AD pathogenesis. While CD36 confers neuroprotection through induction of A β removal, it also activates the NLRP3 inflammasome in microglia and stimulates pro-inflammatory cytokine release (i.e. interleukin IL-1 β and ROS). Thus, microglia may contribute to the toxic environment that induces their own impairment [334, 361, 373, 374]. Moreover, a recent study has demonstrated that the soluble A β_{42} -induced inflammatory milieu directly inhibits microglial phagocytosis of A β_{42} fibrils and downregulates CD36 expression *in vitro* [374]. In sum, it seems the ability of CD36 to initiate A β uptake is differentially regulated by multiple toxic species that accumulate in AD brains.

TREM2

The triggering receptor expressed on myeloid cells 2 protein is a single-pass type 1 transmembrane protein that is part of the immunoglobulin superfamily. Ligands of this receptor include anionic carbohydrates, phospholipids, and apolipoproteins such as ApoE [375–377]. TREM2, along with the protein DAPI2, forms a signaling complex that is responsible for the activation of immune responses in myeloid cells including microglia, macrophages, and monocytes [378]. In AD, however, the predominant TREM2-expressing cell type has been contested [324, 376].

GWASs have recently implicated the R47H variant of *TREM2* as an AD risk factor in multiple populations [96, 155]. In a post-mortem analysis of AD and control brains with and without the R47H variant, the mutation was associated with greater levels of pro-inflammatory markers and increased amyloid load in all brain areas examined [102]. Other *TREM2* risk alleles have also been identified, including R62H and D87N [96, 155]. Remarkably, these mutations and others occur exclusively in the ligand-binding domain of the protein and diminish affinity of the mutant TREM2 to its ligands [377]. It was further demonstrated that myeloid cells can clear A β directly through TREM2-mediated uptake of lipoprotein-A β complexes, modeling the ApoE-A β interactions observed *in vivo* [377]. Moreover, monocytes isolated from AD patients with the R62H variant were unable to clear lipoprotein-A β complexes as efficiently as healthy controls. These findings imply that microglia and monocytes require a functional TREM2 protein to appropriately phagocytose A β .

Studies utilizing ADtg mouse models, however, point to a much more complex role for TREM2 than previously

thought [323, 324, 376]. In one study, *TREM2* knockout in APP/PS1 mice greatly ameliorated disease progression [324], while two other investigations successfully demonstrated *TREM2*-expressing immune cells containing AD pathology [323, 376]. The evidence appears contradictory; however, *TREM2*-modulated neuroinflammation and A β clearance may be highly context-dependent, influenced by the immune cell type and the inflammatory milieu in which it is expressed. In light of this, a recent study has shown that *TREM2*-deficient microglia and monocyte-derived macrophages phagocytose less fibrillar A β_{42} compared to wildtype cells, an impairment partially rescued by therapeutic anti-A β antibodies. Antibody-coated A β greatly enhanced phagocytosis by both *TREM2* knockouts and wildtype cells, although clearance by mutant cells lagged behind controls under all conditions [325]. This finding has important implications for the efficacy of A β -targeted immunotherapies in patients with *TREM2* mutations, yet further research is needed to fully elucidate these relationships.

CD33

CD33 is a member of the sialic acid-binding immunoglobulin-like lectins (SIGLECS) family, expressed on myeloid cells [65, 379]. In general, it is thought to dampen the immune response perhaps by inhibitory signaling through immunoreceptor tyrosine-based inhibition motifs (ITIM) [380]. In the brains of AD patients, CD33-positive microglia are enriched relative to age-matched controls and correlate with greater A β_{42} levels and plaque burden [65]. The diminished capacity of CD33-expressing microglia to phagocytose A β_{42} is thought to explain this relationship. In support of this, possession of the newly discovered rs3865444^C risk allele [33, 34] results in a sevenfold increase in CD33 expression on monocytes with a significant reduction in ability to phagocytose A β_{42} . Monocytes isolated from young individuals with the rs3865444^C risk allele also displayed an A β_{42} phagocytic deficit [64]. Enriched monocytic CD33 expression actually mediated the relationship between this risk allele and higher amyloid plaque burden in AD brains [64]. Conversely, the protective rs3865444^A allele dampens CD33 expression and increases the proportion of CD33 molecules that lack a SIGLEC-specific region responsible for phagocytosis inhibition [379]. These findings provide proof of impaired monocyte-mediated interactions with A β and enhanced disease risk. AD-related immune deficits are thus not solely driven by senescence or the disease process itself. Rather, monocyte phagocytic impairment may far precede A β deposition, as seen in these cases, and arguably predisposes to greater amyloid accumulation and lifetime risk.

Role of monocytes in AD: evidence and controversy

Despite the surging data favoring a critical role of monocytes in AD pathophysiology, it is important to acknowledge the contradictory evidence in the field surrounding monocyte-mediated A β clearance in chronic neurodegenerative diseases. Major questions remain. (1) Under what conditions do monocytes infiltrate the CNS? (2) Do monocytes and macrophages behave differently from microglia once in the CNS parenchyma, especially in their ability to resist misfolded A β forms? (3) Is the neuroprotection exhibited by monocytes a predominantly peripheral blood or a local effect? And (4) Is the effect cell-mediated, molecular or plasma-mediated, or both? The following sections address these controversies given the available literature and identify methodological discrepancies that may have generated some confusion.

Cerebral infiltration of monocytes in murine models of Alzheimer's disease

Monocyte infiltration in AD was first documented by seminal studies transplanting GFP-labeled bone marrow cells into irradiated ADtg mice [295–297, 318]. Monocytes were shown to preferentially home to A β plaques and participate in their clearance [295–297, 318]. The applicability of these studies to normal physiology was later questioned due to the use of whole body irradiation (including brain) and bone marrow transplantation; the former in particular may artificially enhance monocyte infiltration into the brain parenchyma [355, 381]. Specifically, irradiation is known to induce transient BBB leakage, permitting greater passage of cells and blood contents. In addition, whole marrow transplantation increases the number of progenitor cells in the circulation.

To further elucidate the effects of irradiation, the GFP-transplantation paradigm was repeated, this time shielding the heads of recipient mice to conserve BBB integrity. This procedure reduced monocyte infiltration into the CNS, and called into question the conditions necessary for monocyte recruitment [330]. However, several investigations have successfully demonstrated spontaneous monocyte infiltration in the absence of irradiation, genetic manipulation, or chemotherapy (Table 4) [144, 146]. These experiments enriched the peripheral circulation with either CD11b⁺ or CD115⁺ monocytes from the bone marrow of young adult wildtype mice, rather than whole blood marrow, eliminating the additional confounder of increased progenitor cell numbers seen in earlier studies. Importantly, blood enrichment with GFP monocytes in age-matched wildtype (non-ADtg) animals did not cause recruitment of monocytes to the CNS [144, 146], implicating that a diseased-brain is a

precondition for their cerebral recruitment. Taken together, brain irradiation is neither necessary nor sufficient for monocyte recruitment. Rather, several other conditions are consistently required, at least in ADtg models—namely, the presence of amyloid pathology, especially soluble oligomeric or fibrillar A β_{42} forms [382, 383], and binding of the monocytic surface receptor CCR2 to its ligand, MCP-1 [126, 298, 384, 385].

The mechanism by which cerebral amyloid accumulation induces monocyte infiltration is multifactorial. Vascular A β deposition can directly damage the vessel wall [386] and allow greater passage of monocytes into the parenchyma. Indeed, the presence of a leaky BBB was confirmed in 40–60% of AD patients [387, 388]. Furthermore, the A β -induced immune response alters the expression and production of inflammatory cytokines, chemokines, and their receptors [123, 311, 340–342]. The expression of MCP-1, a critical signaling factor for monocyte recruitment, is upregulated near A β plaques, on microglia, and on microvessels in the brains of AD patients and ADtg mice [127, 384, 385]. It is therefore postulated that the AD brain, and specifically chronically activated and overwhelmed microglia, solicit additional assistance from peripheral monocytes through MCP-1 signaling [126, 144, 148, 191, 297, 311, 389]. Other signaling cascades remain poorly understood.

Depletion or enrichment of myeloid cells: impact on cerebral A β burden

Modulation of monocyte recruitment to the CNS clearly demonstrates the significant contribution of monocyte-derived macrophages to A β clearance. Blocking CCR2 signaling [298, 330, 331] or selectively ablating these cells in the blood [296, 297, 328] greatly accelerates A β accumulation in ADtg models. Conversely, inducing monocyte recruitment by lipopolysaccharide (LPS) stimulation, immunization, or monocyte engraftment significantly reduces parenchymal and vascular amyloid pathology in transgenic mice [144–146, 148]. These investigations coupled with compelling *in vitro* data [144, 241] led to the conclusion that monocyte-derived macrophages, compared to their resident counterparts, possess a superior ability to clear fibrillar A β in AD (Fig. 1), resolving inflammation in spite of the toxic environment [240, 241, 296, 297, 300, 390].

Other studies utilizing microglial ablation techniques challenge this assumption. Crossing ADtg mice with the *CD11b-HSVTK* model, in which the thymidine kinase of the herpes simplex virus is expressed under the *CD11b* promoter, allows for elimination of local, proliferating myeloid cells upon intracerebroventricular administration of ganciclovir. Peripheral GFP-labeled macrophages can then

repopulate the CNS, introduced by either transplantation [354] or parabiosis with an actin-enhanced GFP partner [353]. In both cases, repopulation did not augment plaque burden, insoluble A β , or soluble forms. Importantly, macrophages were diffusely spread across the parenchyma, in stark contrast to the plaque-associated microglia of control mice and the demonstrated plaque-homing abilities of monocytes in other models [353, 354]. Given the inability of re-populating monocytes to clear A β , these studies concluded that monocytes do not play a significant role in restricting amyloid pathology. However, it is possible that microglial depletion critically alters the delicate milieu required to induce monocyte phagocytic and anti-inflammatory properties. Indeed, the interplay between microglia, astrocytes, monocytes, and molecular mediators such as scar tissue proteins [i.e. chondroitin sulfate proteoglycans (CSPGs)], has been shown to attract these cells to the lesion sites and induce phenotypic shifts needed for protection in various disease states [144, 145, 148, 191, 297, 348, 367, 391]. Specifically, senescent, plaque-associated microglia are known to release MCP-1 required for monocyte recruitment [126, 298, 384, 385, 389, 392]. In addition, the impact of ganciclovir-induced neurotoxicity is poorly understood. From these repopulation studies, it is apparent that elimination of microglia impacts monocyte phenotype and function, and as such, these findings may not be representative of monocyte behavior in the natural progression of disease.

It is undeniable though that certain conditions do in fact enhance the migratory and A β clearing capacity of infiltrating monocytes over their resident counterparts. In particular, ADtg mice immunized with the myelin-derived peptides MOG45D or GA exhibited reduced A β levels and neuroinflammation, attributable to the increased recruitment of anti-inflammatory monocytes that directly engulfed A β [144, 148]. Other immunomodulatory approaches involving targeted overexpression of A β -degrading enzymes to [145, 146, 191] or genetic manipulation of [322] peripheral monocytes have demonstrated similar monocyte-mediated abrogation of A β deposition [Table 4]. These interventions may form the basis of promising, disease-modifying therapies that will be discussed further below.

Peripheral effects of monocytes on A β clearance

Recognition of the heterogeneity of different monocyte subtypes has emerged from recent studies that identified new functional biomarkers for myelomonocytic cells. An immunohistochemical and activity-based distinction has been proposed between murine monocyte subsets: an inflammatory (Ly6C^{hi}CX3CR1^{int}CCR2⁺) type pertaining to CNS recruitment and parenchymal A β clearance, and a patrolling (Ly6C^{lo}Cx3CR1^{high}CCR2⁻) type that remains

associated with the vasculature [303, 308]. The discussion thus far has exclusively focused on the local effects of the inflammatory subset and their ability to reduce cerebral A β load in the parenchyma through cellular uptake and enzymatic degradation. However, mounting evidence suggests an additional role for patrolling monocytes and perivascular macrophages in the regulation of cerebral amyloid angiopathy (CAA), a disease process in which amyloid plaques accumulate within the walls of small cerebral blood vessels [129, 160]. CAA is seen in over 80% of AD patients and is frequently associated with microhemorrhages and cognitive deficits. Real-time *in vivo* imaging of APP/PS1 mice has elegantly demonstrated that patrolling monocytes are in fact attracted to and crawl along A β -positive veins, where they engulf A β and subsequently recirculate into the bloodstream [329]. To further confirm their role in perivascular A β clearance, depletion of patrolling monocytes substantially increased A β levels in the vasculature [328] as well as in the cortex and hippocampus [329]. A proposed equilibrium of A β clearance exists between the different CNS-associated compartments, including the brain parenchyma, perivascular spaces, CSF, and peripheral blood [328, 393, 394]. Thus, the recirculation of A β -containing monocytes to the periphery may effectively pull other A β species out of the parenchyma—a process termed the peripheral sink effect.

In addition to monocytes and macrophages in the perivascular space, recent data suggest that the activity of these cells in the peripheral blood may be pivotal for the regulation of neuroinflammation associated with AD and for inducing neuronal regeneration [144, 148, 163, 348, 367, 395–397]. Murine parabiosis studies, in which the vasculatures of two mice are joined, have effectively illustrated the impact of peripheral immune cells and, moreover, blood-soluble immune mediators on brain health. Joining the vasculatures of wildtype and ADtg mice, either before or after the onset of A β deposition, reduced A β plaque burden in the cortex and hippocampus of the ADtg parabiont, while also attenuating neuroinflammation, hyperphosphorylated tau, and neuronal apoptosis [397]. This was achieved in the absence of monocyte infiltration or CNS manipulation of known A β clearance pathways. It is therefore inferred that effective A β removal in murine models can be achieved by several mechanisms: either by blood enrichment of wildtype peripheral monocytes to boost infiltration and clearance of A β from brain parenchyma or by replacement and repair of the blood-soluble milieu to induce beneficial phenotypic changes in brain parenchymal cells that promote A β clearance. In support of the latter, earlier studies of parabiosis between young and old wildtype mice demonstrated increased synaptic plasticity, neurogenesis, and cognitive capacity in the older parabionts when sharing blood with young mice [395, 396].

This effect was attributed to the specific milieu in the blood of the younger mice rather than infiltration of peripheral immune cells [395]. Indeed, monocytes release small, soluble mediators, such as cytokines and chemokines, which can traverse the BBB and enter the brain parenchyma. Monocytes were also shown to promote anti-inflammatory behavior of surrounding microglia and astrocytes in several other disease models [144, 145, 148, 191, 297, 348, 367, 391]. Further investigation is greatly needed to understand the signaling that takes place in these models.

Therapeutic effects of peripheral monocytes and macrophages

Given the believed function of monocytes in AD etiology and the ease of access to the peripheral blood, modulation of monocyte phenotype and behavior represents a promising therapeutic target. Though not yet translated into clinical practice, recent investigations in murine models highlight the potential benefit of enhancing monocyte recruitment to the AD brain.

Stimulation with two distinct exogenous compounds has been successful in promoting A β clearance. Dietary curcumin, a major component of the spice turmeric, directly interacts with oligomeric and fibrillar A β ₄₂ [398] and may enhance A β phagocytosis by human PBMCs [315, 399]. Additionally, injections of the macrophage colony-stimulating factor (M-CSF) into APP_{SWE}/PS1 mice prior to signs of cognitive impairment had a number of positive effects. These included increased circulating levels of CD45⁺/CD11b⁺/CD115⁺ monocytes and phagocytic activity of A β by Iba-1⁺ immune cells in brain parenchyma [320], leading to decreased size and density of A β plaques, and prevention of learning and memory deficits [321].

As mentioned above, peripheral immunization with DCs loaded with MOG45D (MOG45D-DC) or with GA also had profound effects on the function of innate immune cells, which consequently reduced various pathological features of AD. In ADtg mice, MOG45D-DC immunization increased CNS recruitment of anti-inflammatory macrophages, demonstrated by reduced TNF- α and increased IL-10 and TGF- β expression, that efficiently phagocytosed A β [148]. As a result, these mice showed restricted vascular and parenchymal A β deposits and reduced soluble A β ₄₂ levels, as well as increased expression of the A β -degrading enzyme MMP-9. GA immunization of ADtg mice yielded the same beneficial immunomodulatory and plaque-clearing effects [144, 297, 348], while also promoting neurogenesis and preservation of synapses and cognitive function [144]. In agreement with these findings, several other studies have shown that suppression of regulatory T-cells, either via peripheral blockade of the programmed cell

death protein-1 (PD-1) [400] or of TGF- β signaling in monocyte-derived macrophages [322], enhanced monocyte recruitment to the brain in ADtg mice, and resulted in A β removal and improved cognitive performance [322, 400].

Other methods of immune modulation include adoptive transfer of healthy monocytes and bone marrow transplantation. Infusion of wildtype CD115⁺ monocytes to the peripheral blood of ADtg mice stimulated their spontaneous migration to amyloid lesions in the absence of irradiation, genetic manipulation, or chemotherapy. Treated mice exhibited reduced cerebral A β protein levels and astrogliosis, preserved pre-synaptic integrity, and ameliorated cognitive deficits [144]. Likewise, bone marrow transplants from wildtype donors increased monocyte recruitment to the CNS at sites of amyloid accumulation, while also reducing plaque burden [295, 297, 318].

Because peripheral monocytes were shown to cross the BBB and home to sites of A β accumulation, they can function as a delivery system of therapeutic agents. Targeted overexpression of either NEP or ACE has proven beneficial in abrogating AD progression in murine models. Injecting 9-month-old ADtg mice with NEP-expressing monocytes completely prevented further A β deposition when compared to untreated ADtg mice or those infused with monocytes containing inactive NEP [146]. Similarly, targeted overexpression of ACE to monocytic cells in the bigenic APP/PS1 mouse model of AD markedly reduced both soluble and insoluble levels of A β ₄₂, limited plaques and astrogliosis, and preserved cognitive function [145, 191].

Conclusion

A β clearance is a complex, multifactorial process, requiring the collaboration of various systems and cell types. A β can be removed to the peripheral circulatory or lymphatic systems by transport across the BBB or by absorption from the CSF and ISF. While innate immune cells are known to phagocytose and degrade fibrillar A β , these cells were only recently shown to engulf and clear soluble A β species as well. It is still unclear whether A β accumulation is a cause or consequence of disease. However, mounting evidence has shown that increased cerebral A β burden is the earliest pathognomonic event in AD. Moreover, soluble, oligomeric A β was shown to directly incite nerve and synaptic damage, leading to impaired neuronal function. In the late-onset, common cases of AD, A β buildup is attributed to defective clearance, rather than to its overproduction. The observed deficiency could result from impairments in any one of the removal processes or, more likely, a combination of minor clearance deficits and compounding risk factors that varies from patient to patient. Modulation of clearance

mechanisms may be an important early strategy for curtailing A β accumulation and disease progression.

As our knowledge of AD continues to expand, so does a body of evidence that supports a key role for innate immune cells, especially monocyte-derived macrophages, in A β removal, local immune regulation, and repair. Bone marrow-derived monocytes can cross the BBB and clear A β through cellular uptake and enzymatic degradation, perhaps even more efficiently than resident microglia. The clearance process is, again, complex. Phagocytosis requires the coordination of many surface receptors (e.g. TLRs, integrins, scavenger receptors) for recognition and uptake, followed by intracellular trafficking, ultimately to lysosomes, for degradation. Monocytes, macrophages, and microglia also mediate extracellular A β degradation through surface expression or release of various proteases, such as ACE, IDE, NEP, and MMP-9. These functions were reported to be markedly impaired in peripheral monocytes isolated from AD patients. It is possible that the observed deficiency is a consequence of immune senescence and AD-related degeneration, or perhaps their dysfunction is a direct contributor to disease development. In support of the latter, possession of a rare variant of the AD-associated *CD33* gene impacts the phagocytic capacity of monocytes isolated from young adult patients, indicating that this particular functional deficit is present throughout life. Other GWAS data have linked multiple immune-related risk factors to AD. Known relationships between the major risk gene *TREM2* and monocyte/microglia phagocytic function offer a compelling demonstration of the immune system's impact in AD.

Aggregates of misfolded A β are known to trigger a prolonged neuroinflammatory response that is tightly associated with synaptic dysfunction and cognitive decline. Enhancing cerebral recruitment of monocytes through either peripheral infusion or immunization with altered myelin-derived antigens was shown to temper these degenerative changes in murine models. Specifically, monocytes were able to efficiently clear A β and resolve the resulting astrogliosis and neuroinflammation, thereby preserving synaptic integrity and cognitive function. Immunomodulation approaches that enhance cerebral recruitment of neuroprotective monocytes hold great promise as disease-modifying therapeutic interventions and represent a valuable target for further application and translation.

Acknowledgements This study was supported by the BrightFocus Foundation (formerly AHAF; M. K-H), The Coins for Alzheimer's Research Trust (C.A.R.T.; M. K-H) Fund, and The Cheryl and Haim Saban and The Marciano Family Foundations (M. K-H). We thank Ms. Hannah Schubloom and Ms. Mia Oviatt for editing assistance.

Compliance with ethical standards

Conflict of interest The authors declare no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Hebert LE, Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. *Neurology* 80(19):1778–1783. doi:10.1212/WNL.0b013e31828726f5
2. Prince M, Wimo A, Guerchet M, Ali G, Wu Y, Prina M (2015) World Alzheimer Report 2015: the global impact of dementia. Alzheimer's Disease International, London
3. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. *Science* 298(5594):789–791. doi:10.1126/science.1074069
4. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev* 81(2):741–766
5. Holmes BB, Diamond MI (2014) Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target. *J Biol Chem* 289(29):19855–19861. doi:10.1074/jbc.R114.549295
6. Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. *Nature* 501(7465):45–51. doi:10.1038/nature12481
7. Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med* 8(6):595–608. doi:10.15252/emmm.201606210
8. Meli G, Lecci A, Manca A, Krako N, Albertini V, Benussi L, Ghidoni R, Cattaneo A (2014) Conformational targeting of intracellular Abeta oligomers demonstrates their pathological oligomerization inside the endoplasmic reticulum. *Nat Commun* 5:3867. doi:10.1038/ncomms4867
9. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, Schwartz M, Farkas DL (2011) Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. *NeuroImage* 54 Suppl 1:S204–217. doi:10.1016/j.neuroimage.2010.06.020
10. Koronyo Y, Salumbides BC, Black KL, Koronyo-Hamaoui M (2012) Alzheimer's disease in the retina: imaging retinal abeta plaques for early diagnosis and therapy assessment. *Neurodegener Dis* 10(1–4):285–293. doi:10.1159/000335154
11. La Morgia C, Ross-Cisneros FN, Koronyo Y, Hannibal J, Gallassi R, Cantalupo G, Sambati L, Pan BX, Tozer KR, Barboni P, Provini F, Avanzini P, Carbonelli M, Pelosi A, Chui H, Liguori R, Baruzzi A, Koronyo-Hamaoui M, Sadun AA, Carelli V (2016) Melanopsin retinal ganglion cell loss in Alzheimer disease. *Ann Neurol* 79(1):90–109. doi:10.1002/ana.24548
12. Tsai Y, Lu B, Ljubimov AV, Girman S, Ross-Cisneros FN, Sadun AA, Svendsen CN, Cohen RM, Wang S (2014) Ocular changes in TgF344-AD rat model of Alzheimer's disease. *Investig Ophthalmol Vis Sci* 55(1):523–534. doi:10.1167/iops.13-12888
13. Hart NJ, Koronyo Y, Black KL, Koronyo-Hamaoui M (2016) Ocular indicators of Alzheimer's: exploring disease in the retina. *Acta Neuropathol (Berl)* 132(6):767–787. doi:10.1007/s00401-016-1613-6
14. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. *N Engl J Med* 362(4):329–344. doi:10.1056/NEJMra0909142
15. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 297(5580):353–356. doi:10.1126/science.1072994
16. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dement J Alzheimer's Assoc* 7(3):280–292. doi:10.1016/j.jalz.2011.03.003
17. Haass C, Kaether C, Thinakaran G, Sisodia S (2012) Trafficking and proteolytic processing of APP. *Cold Spring Harb Perspect Med* 2(5):a006270. doi:10.1101/cshperspect.a006270
18. Haass C, Hung AY, Selkoe DJ, Teplow DB (1994) Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. *J Biol Chem* 269(26):17741–17748
19. Zigman WB, Devenny DA, Krinsky-McHale SJ, Jenkins EC, Urv TK, Wegiel J, Schupf N, Silverman W (2008) Alzheimer's disease in adults with down syndrome. *Int Rev Res Ment Retard* 36:103–145. doi:10.1016/s0074-7750(08)00004-9
20. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. *Neuron* 17(5):1005–1013
21. Karch CM, Goate AM (2015) Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biol Psychiatry* 77(1):43–51. doi:10.1016/j.biopsych.2014.05.006
22. Nicolas G, Wallon D, Charbonnier C, Quenez O, Rousseau S, Richard AC, Rovelet-Lecrux A, Coutant S, Le Guennec K, Bacq D, Garnier JG, Olaso R, Boland A, Meyer V, Deleuze JF, Munter HM, Bourque G, Auld D, Montpetit A, Lathrop M, Guyant-Marechal L, Martinaud O, Pariente J, Rollin-Sillaire A, Pasquier F, Le Ber I, Sarazin M, Croisile B, Boutoleau-Bretonniere C, Thomas-Anterion C, Paquet C, Sauvee M, Moreaud O, Gabelle A, Sellal F, Ceccaldi M, Chamard L, Blanc F, Frebourg T, Campion D, Hannequin D (2016) Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. *Eur J Hum Genet* 24(5):710–716. doi:10.1038/ejhg.2015.173
23. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nat Med* 2(8):864–870
24. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreasson OA, Jonsson EG, Palotie A, Behrens TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K (2012) A mutation in APP

- protects against Alzheimer's disease and age-related cognitive decline. *Nature* 488(7409):96–99. doi:10.1038/nature11283
25. Benilova I, Gallardo R, Ungureanu AA, Castillo Cano V, Snellinx A, Ramakers M, Bartic C, Rousseau F, Schymkowitz J, De Strooper B (2014) The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-beta (A β) aggregation. *J Biol Chem* 289(45):30977–30989. doi:10.1074/jbc.M114.599027
 26. Cruchaga C, Haller G, Chakraverty S, Mayo K, Vallania FL, Mitra RD, Faber K, Williamson J, Bird T, Diaz-Arrastia R, Foroud TM, Boeve BF, Graff-Radford NR, St Jean P, Lawson M, Ehm MG, Mayeux R, Goate AM (2012) Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. *PLoS one* 7(2):e31039. doi:10.1371/journal.pone.0031039
 27. Sleegers K, Brouwers N, Gijselink I, Theuns J, Goossens D, Wauters J, Del-Favero J, Cruts M, van Duijn CM, Van Broeckhoven C (2006) APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. *Brain J Neurol* 129(Pt 11):2977–2983. doi:10.1093/brain/awl203
 28. Guerreiro RJ, Gustafson DR, Hardy J (2012) The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. *Neurobiol Aging* 33(3):437–456. doi:10.1016/j.neurobiolaging.2010.03.025
 29. Hutton M, Busfield J, Wrang M, Crook R, Perez-Tur J, Clark RF, Prihar G, Talbot C, Phillips H, Wright K, Baker M, Lendon C, Duff K, Martinez A, Houlden H, Nichols A, Karran E, Roberts G, Roques P, Rossor M, Venter JC, Adams MD, Cline RT, Phillips CA, Goate A et al (1996) Complete analysis of the presenilin 1 gene in early onset Alzheimer's disease. *Neuroreport* 7(3):801–805
 30. Barton AJ, Crook BW, Karran EH, Brown F, Dewar D, Mann DM, Pearson RC, Graham DI, Hardy J, Hutton M, Duff K, Goate AM, Clark RF, Roberts GW (1996) Alteration in brain presenilin 1 mRNA expression in early onset familial Alzheimer's disease. *Neurodegeneration* 5(3):213–218
 31. Chouraki V, Seshadri S (2014) Genetics of Alzheimer's disease. *Adv Genet* 87:245–294. doi:10.1016/b978-0-12-800149-3.00005-6
 32. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thornton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Moron FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fievet N, Huentelman MW, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuinness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossu P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razaquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH, Jr., Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JJ, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltunen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nothen MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nature genetics* 45(12):1452–1458. doi:10.1038/ng.2802
 33. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Rutherford E, Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Gallacher J, Hull M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, van Duijn CM, Breteler MM, Ikram MA, DeStafano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S, Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alperovitch A, Lathrop M, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefanov H, Stefansson K, Snaedal J, Bjornsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossu P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastrro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet* 43(5):429–435. doi:10.1038/ng.803
 34. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buross J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA,

- Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet* 43(5):436–441. doi:10.1038/ng.801
35. Chan SL, Kim WS, Kwok JB, Hill AF, Cappai R, Rye KA, Garner B (2008) ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. *J Neurochem* 106(2):793–804. doi:10.1111/j.1471-4159.2008.05433.x
36. Kim WS, Li H, Ruberu K, Chan S, Elliott DA, Low JK, Cheng D, Karl T, Garner B (2013) Deletion of Abca7 increases cerebral amyloid-beta accumulation in the J20 mouse model of Alzheimer's disease. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 33(10):4387–4394. doi:10.1523/jneurosci.4165-12.2013
37. Shulman JM, Chen K, Keenan BT, Chibnik LB, Fleisher A, Thiyyagura P, Roontiva A, McCabe C, Patsopoulos NA, Corneveaux JJ, Yu L, Huentelman MJ, Evans DA, Schneider JA, Reiman EM, De Jager PL, Bennett DA (2013) Genetic susceptibility for Alzheimer disease neuritic plaque pathology. *JAMA Neurol* 70(9):1150–1157. doi:10.1001/jamaneurol.2013.2815
38. Satoh K, Abe-Dohmae S, Yokoyama S, St George-Hyslop P, Fraser PE (2015) ATP-binding cassette transporter A7 (ABCA7) loss of function alters Alzheimer amyloid processing. *J Biol Chem* 290(40):24152–24165. doi:10.1074/jbc.M115.655076
39. Fu Y, Hsiao JH, Paxinos G, Halliday GM, Kim WS (2016) ABCA7 Mediates Phagocytic Clearance of Amyloid-beta in the. *Brain J Alzheimer's Dis JAD* 54(2):569–584. doi:10.3233/jad-160456
40. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF (2010) ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. *Embo j* 29(17):3020–3032. doi:10.1038/emboj.2010.167
41. Marcinkiewicz M, Seidah NG (2000) Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain. *J Neurochem* 75(5):2133–2143
42. Suh J, Choi SH, Romano DM, Gannon MA, Lesinski AN, Kim DY, Tanzi RE (2013) ADAM10 missense mutations potentiate beta-amyloid accumulation by impairing prodomain chaperone function. *Neuron* 80(2):385–401. doi:10.1016/j.neuron.2013.08.035
43. Kim M, Suh J, Romano D, Truong MH, Mullin K, Hooli B, Norton D, Tesco G, Elliott K, Wagner SL, Moir RD, Becker KD, Tanzi RE (2009) Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. *Hum Mol Genet* 18(20):3987–3996. doi:10.1093/hmg/ddp323
44. Jochemsen HM, Teunissen CE, Ashby EL, van der Flier WM, Jones RE, Geerlings MI, Scheltens P, Kehoe PG, Muller M (2014) The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. *Alzheimer's Res Ther* 6(3):27. doi:10.1186/alzrt257
45. Kehoe PG, Russ C, McIlroy S, Williams H, Holmans P, Holmes C, Liolitsa D, Vahidassr D, Powell J, McGleenon B, Liddell M, Plomin R, Dynan K, Williams N, Neal J, Cairns NJ, Wilcock G, Passmore P, Lovestone S, Williams J, Owen MJ (1999) Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. *Nat Genet* 21(1):71–72. doi:10.1038/5009
46. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. *Nat Genet* 39(1):17–23. doi:10.1038/ng1934
47. Lehmann DJ, Cortina-Borja M, Warden DR, Smith AD, Sleegers K, Prince JA, van Duijn CM, Kehoe PG (2005) Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. *Am J Epidemiol* 162(4):305–317. doi:10.1093/aje/kwi202
48. Chou PS, Wu MN, Chou MC, Chien I, Yang YH (2016) Angiotensin-converting enzyme insertion/deletion polymorphism and the longitudinal progression of Alzheimer's disease. *Geriatr Gerontol Int*. doi:10.1111/ggi.12929
49. Kauwe JS, Bailey MH, Ridge PG, Perry R, Wadsworth ME, Hoyt KL, Staley LA, Karch CM, Harari O, Cruchaga C, Ainscough BJ, Bales K, Pickering EH, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Goate AM (2014) Genome-wide association study of CSF levels of 59 Alzheimer's disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. *PLoS Genet* 10(10):e1004758. doi:10.1371/journal.pgen.1004758
50. Edwards TL, Pericak-Vance M, Gilbert JR, Haines JL, Martin ER, Ritchie MD (2009) An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3. *Am J Med Genet Part B Neuropsychiatr Genet* 150b(5):721–735. doi:10.1002/ajmg.b.30899
51. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* 261(5123):921–923
52. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. *Sci Transl Med* 3(89):89ra57. doi:10.1126/scitranslmed.3002156
53. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. *J Clin Invest* 118(12):4002–4013. doi:10.1172/jci36663
54. Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C, Holtzman DM (2013) ApoE influences amyloid-beta (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. *Proc Natl Acad Sci USA* 110(19):E1807–E1816. doi:10.1073/pnas.1220484110
55. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM (1999) Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. *Proc Natl Acad Sci USA* 96(26):15233–15238
56. Conejero-Goldberg C, Gomar JJ, Bobes-Bascaran T, Hyde TM, Kleinman JE, Herman MM, Chen S, Davies P, Goldberg TE (2014) APOE2 enhances neuroprotection against Alzheimer's

- disease through multiple molecular mechanisms. *Mol Psychiatry* 19(11):1243–1250. doi:10.1038/mp.2013.194
57. Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ, Corneveaux JJ, Hardy J, Vonsattel JP, Younkin SG, Bennett DA, De Jager PL, Larson EB, Crane PK, Kambh MI, Kofler JK, Mash DC, Duque L, Gilbert JR, Gwirtsman H, Buxbaum JD, Kramer P, Dickson DW, Farrer LA, Frosch MP, Ghetti B, Haines JL, Hyman BT, Kukull WA, Mayeux RP, Pericak-Vance MA, Schneider JA, Trojanowski JQ, Reiman EM, Schellenberg GD, Montine TJ (2014) Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias. *PLoS Genet* 10(9):e1004606. doi:10.1371/journal.pgen.1004606
 58. Rezaadeh M, Khorrami A, Yeghaneh T, Talebi M, Kiani SJ, Heshmati Y, Ghahsouran J (2016) Genetic factors affecting late-onset Alzheimer's disease susceptibility. *Neuromol Med* 18(1):37–49. doi:10.1007/s12017-015-8376-4
 59. Miyagawa T, Ebinuma I, Morohashi Y, Hori Y, Young Chang M, Hattori H, Maehara T, Yokoshima S, Fukuyama T, Tsuji S, Iwatsubo T, Prendergast GC, Tomita T (2016) BIN1 regulates BACE1 intracellular trafficking and amyloid-beta production. *Hum Mol Genet*. doi:10.1093/hmg/ddw146
 60. Chapuis J, Hansmannel F, Gistelinc M, Mounier A, Van Cauwenberghe C, Kolen KV, Geller F, Sottejeau Y, Harold D, Dourlen P, Grenier-Boley B, Kamatani Y, Delepine B, Demiautte F, Zelenika D, Zommer N, Hamdane M, Bellenguez C, Dartigues JF, Hauw JJ, Letronne F, Ayril AM, Sleegers K, Schellens A, Broeck LV, Engelborghs S, De Deyn PP, Vandenberghe R, O'Donovan M, Owen M, Epelbaum J, Mercken M, Karran E, Bantscheff M, Drewes G, Joberty G, Campion D, Octave JN, Berr C, Lathrop M, Callaerts P, Mann D, Williams J, Buee L, Dewachter I, Van Broeckhoven C, Amouyel P, Moechars D, Dermaut B, Lambert JC (2013) Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology. *Mol Psychiatry* 18(11):1225–1234. doi:10.1038/mp.2013.1
 61. Tan MS, Yu JT, Tan L (2013) Bridging integrator 1 (BIN1): form, function, and Alzheimer's disease. *Trends Mol Med* 19(10):594–603. doi:10.1016/j.molmed.2013.06.004
 62. Cormont M, Meton I, Mari M, Monzo P, Keslair F, Gaskin C, McGraw TE, Le Marchand-Brustel Y (2003) CD2AP/CMS regulates endosome morphology and traffic to the degradative pathway through its interaction with Rab4 and c-Cbl. *Traffic* 4(2):97–112
 63. Liao F, Jiang H, Srivatsan S, Xiao Q, Lefton KB, Yamada K, Mahan TE, Lee JM, Shaw AS, Holtzman DM (2015) Effects of CD2-associated protein deficiency on amyloid-beta in neuroblastoma cells and in an APP transgenic mouse model. *Mol Neurodegener* 10:12. doi:10.1186/s13024-015-0006-y
 64. Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboywa S, Lee M, Von Korff A, Morris MC, Evans DA, Johnson K, Sperling RA, Schneider JA, Bennett DA, De Jager PL (2013) CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. *Nat Neurosci* 16(7):848–850. doi:10.1038/nn.3435
 65. Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, Hyman BT, Tanzi RE (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. *Neuron* 78(4):631–643. doi:10.1016/j.neuron.2013.04.014
 66. Mao YF, Guo ZY, Pu JL, Chen YX, Zhang BR (2015) Association of CD33 and MS4A cluster variants with Alzheimer's disease in East Asian populations. *Neurosci Lett* 609:235–239. doi:10.1016/j.neulet.2015.10.007
 67. Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BM, Hooli B, Divito J, Ionita I, Jiang H, Laird N, Moscarillo T, Ohlsen KL, Elliott K, Wang X, Hu-Lince D, Ryder M, Murphy A, Wagner SL, Blacker D, Becker KD, Tanzi RE (2008) Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. *Am J Hum Genet* 83(5):623–632. doi:10.1016/j.ajhg.2008.10.008
 68. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, Zlokovic BV (2007) Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. *J Cereb Blood Flow Metab* 27(5):909–918. doi:10.1038/sj.jcbfm.9600419
 69. Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, Rozovsky I, Stine WB, Snyder SW, Holtzman TF et al (1995) Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1–42) and forms slowly sedimenting A beta complexes that cause oxidative stress. *Exp Neurol* 136(1):22–31
 70. Matsubara E, Frangione B, Ghiso J (1995) Characterization of apolipoprotein J-Alzheimer's A beta interaction. *J Biol Chem* 270(13):7563–7567
 71. Matsubara E, Soto C, Governale S, Frangione B, Ghiso J (1996) Apolipoprotein J and Alzheimer's amyloid beta solubility. *Biochem J* 316(Pt 2):671–679
 72. Yerbury JJ, Poon S, Meehan S, Thompson B, Kumita JR, Dobson CM, Wilson MR (2007) The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. *FASEB J Off Publ Feder Am Soc Exp Biol* 21(10):2312–2322. doi:10.1096/fj.06-7986com
 73. Nuutinen T, Huuskonen J, Suuronen T, Ojala J, Miettinen R, Salminen A (2007) Amyloid-beta 1–42 induced endocytosis and clusterin/apoJ protein accumulation in cultured human astrocytes. *Neurochem Int* 50(3):540–547. doi:10.1016/j.neuint.2006.11.002
 74. Nuutinen T, Suuronen T, Kauppinen A, Salminen A (2009) Clusterin: a forgotten player in Alzheimer's disease. *Brain Res Rev* 61(2):89–104. doi:10.1016/j.brainresrev.2009.05.007
 75. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM (2004) ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. *Neuron* 41(2):193–202
 76. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hilltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet* 41(10):1094–1099. doi:10.1038/ng.439
 77. Karch CM, Jeng AT, Nowotny P, Cady J, Cruchaga C, Goate AM (2012) Expression of novel Alzheimer's disease risk genes in control and Alzheimer's disease brains. *PLoS one* 7(11):e50976. doi:10.1371/journal.pone.0050976
 78. Crehan H, Hardy J, Pocock J (2013) Blockage of CR1 prevents activation of rodent microglia. *Neurobiol Dis* 54:139–149. doi:10.1016/j.nbd.2013.02.003
 79. Giri M, Zhang M, Lu Y (2016) Genes associated with Alzheimer's disease: an overview and current status. *Clinical interventions in aging* 11:665–681. doi:10.2147/cia.s105769
 80. Schellenberg GD, Montine TJ (2012) The genetics and neuropathology of Alzheimer's disease. *Acta Neuropathol (Berl)* 124(3):305–323. doi:10.1007/s00401-012-0996-2
 81. Sakamoto A, Sugamoto Y, Tokunaga Y, Yoshimuta T, Hayashi K, Konno T, Kawashiri MA, Takeda Y, Yamagishi M (2011)

- Expression profiling of the ephrin (EFN) and Eph receptor (EPH) family of genes in atherosclerosis-related human cells. *J Int Med Res* 39(2):522–527
82. Lai KO, Ip NY (2009) Synapse development and plasticity: roles of ephrin/Eph receptor signaling. *Curr Opin Neurobiol* 19(3):275–283. doi:[10.1016/j.conb.2009.04.009](https://doi.org/10.1016/j.conb.2009.04.009)
 83. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvin V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, Heun R, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet* 41(10):1088–1093. doi:[10.1038/ng.440](https://doi.org/10.1038/ng.440)
 84. Miller SE, Sahlender DA, Graham SC, Honing S, Robinson MS, Peden AA, Owen DJ (2011) The molecular basis for the endocytosis of small R-SNAREs by the clathrin adaptor CALM. *Cell* 147(5):1118–1131. doi:[10.1016/j.cell.2011.10.038](https://doi.org/10.1016/j.cell.2011.10.038)
 85. Miller SE, Mathiasen S, Bright NA, Pierre F, Kelly BT, Kladt N, Schauss A, Merrifield CJ, Stamou D, Honing S, Owen DJ (2015) CALM regulates clathrin-coated vesicle size and maturation by directly sensing and driving membrane curvature. *Dev Cell* 33(2):163–175. doi:[10.1016/j.devcel.2015.03.002](https://doi.org/10.1016/j.devcel.2015.03.002)
 86. Xiao Q, Gil SC, Yan P, Wang Y, Han S, Gonzales E, Perez R, Cirrito JR, Lee JM (2012) Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis. *J Biol Chem* 287(25):21279–21289. doi:[10.1074/jbc.M111.338376](https://doi.org/10.1074/jbc.M111.338376)
 87. Kanatsu K, Morohashi Y, Suzuki M, Kuroda H, Watanabe T, Tomita T, Iwatsubo T (2014) Decreased CALM expression reduces Abeta42 to total Abeta ratio through clathrin-mediated endocytosis of gamma-secretase. *Nature communications* 5:3386. doi:[10.1038/ncomms4386](https://doi.org/10.1038/ncomms4386)
 88. Tian Y, Chang JC, Fan EY, Flajolet M, Greengard P (2013) Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer's APP-CTF for terminal degradation via autophagy. *Proc Natl Acad Sci USA* 110(42):17071–17076. doi:[10.1073/pnas.1315110110](https://doi.org/10.1073/pnas.1315110110)
 89. Parikh I, Fardo DW, Estus S (2014) Genetics of PICALM expression and Alzheimer's disease. *PLoS One* 9(3):e91242. doi:[10.1371/journal.pone.0091242](https://doi.org/10.1371/journal.pone.0091242)
 90. Chen J, Zhou Y, Mueller-Steiner S, Chen LF, Kwon H, Yi S, Mucke L, Gan L (2005) SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. *J Biol Chem* 280(48):40364–40374. doi:[10.1074/jbc.M509329200](https://doi.org/10.1074/jbc.M509329200)
 91. Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, Zhao W, Thiagarajan M, MacGrogan D, Rodgers JT, Puigserver P, Sadoshima J, Deng H, Pedrini S, Gandy S, Sauve AA, Pasinetti GM (2006) Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. *J Biol Chem* 281(31):21745–21754. doi:[10.1074/jbc.M602909200](https://doi.org/10.1074/jbc.M602909200)
 92. Jesko H, Wencel P, Strosznajder RP, Strosznajder JB (2016) Sirtuins and their roles in brain aging and neurodegenerative disorders. *Neurochem Res*. doi:[10.1007/s11064-016-2110-y](https://doi.org/10.1007/s11064-016-2110-y)
 93. Corpas R, Revilla S, Ursulet S, Castro-Freire M, Kaliman P, Petegnief V, Gimenez-Llort L, Sarkis C, Pallas M, Sanfeliu C (2016) SIRT1 overexpression in mouse hippocampus induces cognitive enhancement through proteostatic and neurotrophic mechanisms. *Mol Neurobiol*. doi:[10.1007/s12035-016-0087-9](https://doi.org/10.1007/s12035-016-0087-9)
 94. Wang Z, Lei H, Zheng M, Li Y, Cui Y, Hao F (2016) Meta-analysis of the association between Alzheimer disease and variants in GAB2, PICALM, and SORL1. *Mol Neurobiol* 53(9):6501–6510. doi:[10.1007/s12035-015-9546-y](https://doi.org/10.1007/s12035-015-9546-y)
 95. Xue X, Zhang M, Lin Y, Xu E, Jia J (2014) Association between the SORL1 rs2070045 polymorphism and late-onset Alzheimer's disease: interaction with the ApoE genotype in the Chinese Han population. *Neurosci Lett* 559:94–98. doi:[10.1016/j.neulet.2013.11.042](https://doi.org/10.1016/j.neulet.2013.11.042)
 96. Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K (2013) Variant of TREM2 associated with the risk of Alzheimer's disease. *N Engl J Med* 368(2):107–116. doi:[10.1056/NEJMoa1211103](https://doi.org/10.1056/NEJMoa1211103)
 97. Herskowitz JH, Offe K, Deshpande A, Kahn RA, Levey AI, Lah JJ (2012) GGA1-mediated endocytic traffic of LR11/SorLA alters APP intracellular distribution and amyloid-beta production. *Mol Biol Cell* 23(14):2645–2657. doi:[10.1091/mbc.E12-01-0014](https://doi.org/10.1091/mbc.E12-01-0014)
 98. Fjorback AW, Seaman M, Gustafsen C, Mehmedbasic A, Gokool S, Wu C, Militz D, Schmidt V, Madsen P, Nyegaard JR, Willnow TE, Christensen EI, Mobley WB, Nykjaer A, Andersen OM (2012) Retromer binds the FANSHY sorting motif in SorLA to regulate amyloid precursor protein sorting and processing. *J Neurosci Off J Soc Neurosci* 32(4):1467–1480. doi:[10.1523/jneurosci.2272-11.2012](https://doi.org/10.1523/jneurosci.2272-11.2012)
 99. Schmidt V, Baum K, Lao A, Rateitschak K, Schmitz Y, Teichmann A, Wiesner B, Petersen CM, Nykjaer A, Wolf J, Wolkenhauer O, Willnow TE (2012) Quantitative modelling of amyloidogenic processing and its influence by SORLA in Alzheimer's disease. *Embo j* 31(1):187–200. doi:[10.1038/emboj.2011.352](https://doi.org/10.1038/emboj.2011.352)
 100. Schmidt V, Sporbert A, Rohe M, Reimer T, Rehm A, Andersen OM, Willnow TE (2007) SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1. *J Biol Chem* 282(45):32956–32964. doi:[10.1074/jbc.M705073200](https://doi.org/10.1074/jbc.M705073200)
 101. Sager KL, Wu J, Leurgans SE, Rees HD, Gearing M, Mufson EJ, Levey AI, Lah JJ (2007) Neuronal LR11/sorLA expression is reduced in mild cognitive impairment. *Ann Neurol* 62(6):640–647. doi:[10.1002/ana.21190](https://doi.org/10.1002/ana.21190)
 102. Roussos P, Katsel P, Fam P, Tan W, Purohit DP, Haroutunian V (2015) The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia. *Alzheimer's Dement J Alzheimer's Assoc* 11(10):1163–1170. doi:[10.1016/j.jalz.2014.10.013](https://doi.org/10.1016/j.jalz.2014.10.013)
 103. Takahashi K, Prinz M, Stagi M, Chechneva O, Neumann H (2007) TREM2-transduced myeloid precursors mediate nervous tissue debris clearance and facilitate recovery in an animal model of multiple sclerosis. *PLoS Med* 4(4):e124. doi:[10.1371/journal.pmed.0040124](https://doi.org/10.1371/journal.pmed.0040124)
 104. Takahashi K, Rochford CD, Neumann H (2005) Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. *J Exp Med* 201(4):647–657. doi:[10.1084/jem.20041611](https://doi.org/10.1084/jem.20041611)

105. Hsieh CL, Koike M, Spusta SC, Niemi EC, Yenari M, Nakamura MC, Seaman WE (2009) A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. *J Neurochem* 109(4):1144–1156. doi:[10.1111/j.1471-4159.2009.06042.x](https://doi.org/10.1111/j.1471-4159.2009.06042.x)
106. Hamerman JA, Jarjoura JR, Humphrey MB, Nakamura MC, Seaman WE, Lanier LL (2006) Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. *Journal of immunology* (Baltimore, Md : 1950) 177 (4):2051–2055
107. Turnbull IR, Gilfillan S, Cella M, Aoshi T, Miller M, Piccio L, Hernandez M, Colonna M (2006) Cutting edge: TREM-2 attenuates macrophage activation. *Journal of immunology* (Baltimore, Md : 1950) 177 (6):3520–3524
108. Pottier C, Wallon D, Rousseau S, Rovelet-Lecrux A, Richard AC, Rollin-Sillaire A, Frebourg T, Campion D, Hannequin D (2013) TREM2 R47H variant as a risk factor for early-onset Alzheimer's disease. *Journal of Alzheimer's disease : JAD* 35(1):45–49. doi:[10.3233/jad-122311](https://doi.org/10.3233/jad-122311)
109. Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, Chott R, Yarasheski KE, Holtzman DM, Morris JC, Benzinger TL, Bateman RJ (2013) Increased in vivo amyloid-beta42 production, exchange, and loss in presenilin mutation carriers. *Sci Transl Med* 5(189):189ra177. doi:[10.1126/scitranslmed.3005615](https://doi.org/10.1126/scitranslmed.3005615)
110. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. *Science* 330(6012):1774. doi:[10.1126/science.1197623](https://doi.org/10.1126/science.1197623)
111. Kaye R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science* 300(5618):486–489. doi:[10.1126/science.1079469](https://doi.org/10.1126/science.1079469)
112. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nature reviews Molecular cell biology* 8 (2):101–112. doi:[10.1038/nrm2101](https://doi.org/10.1038/nrm2101)
113. Lesné S, Koh MT, Kotilinek L, Kaye R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-beta protein assembly in the brain impairs memory. *Nature* 440(7082):352–357. doi:[10.1038/nature04533](https://doi.org/10.1038/nature04533)
114. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. *Ann Neurol* 46(6):860–866
115. Mc Donald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, Selkoe DJ, Ince PG, Walsh DM (2010) The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. *Brain : a journal of neurology* 133 (Pt 5):1328–1341. doi:[10.1093/brain/awq065](https://doi.org/10.1093/brain/awq065)
116. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* 416(6880):535–539. doi:[10.1038/416535a](https://doi.org/10.1038/416535a)
117. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. *Nat Neurosci* 8(1):79–84. doi:[10.1038/nn1372](https://doi.org/10.1038/nn1372)
118. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat Med* 14(8):837–842. doi:[10.1038/nm1782](https://doi.org/10.1038/nm1782)
119. Viola KL, Klein WL (2015) Amyloid beta oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. *Acta Neuropathol (Berl)* 129(2):183–206. doi:[10.1007/s00401-015-1386-3](https://doi.org/10.1007/s00401-015-1386-3)
120. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP (1997) Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 17(3):1046–1054
121. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, Yan SD (2005) Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. *FASEB J* 19 (14):2040–2041. doi:[10.1096/fj.05-3735fje](https://doi.org/10.1096/fj.05-3735fje)
122. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. *Hum Mol Genet* 15(9):1437–1449. doi:[10.1093/hmg/ddl066](https://doi.org/10.1093/hmg/ddl066)
123. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP (2015) Neuroinflammation in Alzheimer's disease. *Lancet Neurol* 14(4):388–405. doi:[10.1016/s1474-4422\(15\)70016-5](https://doi.org/10.1016/s1474-4422(15)70016-5)
124. Mosher KI, Wyss-Coray T (2014) Microglial dysfunction in brain aging and Alzheimer's disease. *Biochem Pharmacol* 88(4):594–604. doi:[10.1016/j.bcp.2014.01.008](https://doi.org/10.1016/j.bcp.2014.01.008)
125. Fiala M, Lin J, Ringman J, Kermani-Arab V, Tsao G, Patel A, Lossinsky AS, Graves MC, Gustavson A, Sayre J, Sofroni E, Suarez T, Chiappelli F, Bernard G (2005) Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. *Journal of Alzheimer's disease : JAD* 7(3):221–232 **discussion 255–262**
126. Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M, Witte M, Lorton D, Kuo YM, Roher AE (1998) Amyloid-beta induces chemokine secretion and monocyte migration across a human blood-brain barrier model. *Mol Med* 4(7):480–489
127. Saresella M, Marventano I, Calabrese E, Piancone F, Rainone V, Gatti A, Alberoni M, Nemni R, Clerici M (2014) A complex proinflammatory role for peripheral monocytes in Alzheimer's disease. *JAD* 38(2):403–413. doi:[10.3233/jad-131160](https://doi.org/10.3233/jad-131160)
128. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N (1996) Oxidative damage in Alzheimer's. *Nature* 382(6587):120–121. doi:[10.1038/382120b0](https://doi.org/10.1038/382120b0)
129. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. *Acta Neuropathol (Berl)* 118(1):103–113. doi:[10.1007/s00401-009-0522-3](https://doi.org/10.1007/s00401-009-0522-3)
130. Frost S, Guymer R, Aung KZ, Macaulay SL, Sohrabi HR, Bourgeat P, Salvado O, Rowe CC, Ames D, Masters CL, Martins RN, Kanagasingam Y, Group AT (2016) Alzheimer's disease and the early signs of age-related macular degeneration. *Curr Alzheimer Res* 13(11):1259–1266. doi:[10.2174/1567205013666160603003800](https://doi.org/10.2174/1567205013666160603003800)
131. Kimbrough IF, Robel S, Roberson ED, Sontheimer H (2015) Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer's disease. *Brain J Neurol* 138(Pt 12):3716–3733. doi:[10.1093/brain/awv327](https://doi.org/10.1093/brain/awv327)

132. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE (2004) Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. *Arch Neurol* 61(3):378–384. doi:[10.1001/archneur.61.3.378](https://doi.org/10.1001/archneur.61.3.378)
133. Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, Rawal B, Parisi JE, Petersen RC, Kantarci K, Ross OA, Duara R, Knopman DS, Jack CR, Dickson DW (2015) Clinicopathologic and 11 C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. *Brain J Neurol* 138(Pt 5):1370–1381. doi:[10.1093/brain/awv050](https://doi.org/10.1093/brain/awv050)
134. Karran E, Hardy J (2014) A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. *Ann Neurol* 76(2):185–205. doi:[10.1002/ana.24188](https://doi.org/10.1002/ana.24188)
135. Morris GP, Clark IA, Vissel B (2014) Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. *Acta Neuropathol Commun* 2:135. doi:[10.1186/s40478-014-0135-5](https://doi.org/10.1186/s40478-014-0135-5)
136. Chen M, Maleski JJ, Sawmiller DR (2011) Scientific truth or false hope? Understanding Alzheimer's disease from an aging perspective. *JAD* 24(1):3–10. doi:[10.3233/jad-2010-101638](https://doi.org/10.3233/jad-2010-101638)
137. Herrup K (2010) Reimagining Alzheimer's disease—an age-based hypothesis. *J Neurosci* 30(50):16755–16762. doi:[10.1523/jneurosci.4521-10.2010](https://doi.org/10.1523/jneurosci.4521-10.2010)
138. Morris GP, Clark IA, Zinn R, Vissel B (2013) Microglia: a new frontier for synaptic plasticity, learning and memory, and neurodegenerative disease research. *Neurobiol Learn Mem* 105:40–53. doi:[10.1016/j.nlm.2013.07.002](https://doi.org/10.1016/j.nlm.2013.07.002)
139. Kandimalla R, Thirumala V, Reddy PH (2016) Is Alzheimer's disease a Type 3 diabetes? A critical appraisal. *Biochim Biophys Acta*. doi:[10.1016/j.bbadis.2016.08.018](https://doi.org/10.1016/j.bbadis.2016.08.018)
140. Götz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301 tau transgenic mice induced by Abeta 42 fibrils. *Science* 293(5534):1491–1495. doi:[10.1126/science.1062097](https://doi.org/10.1126/science.1062097)
141. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. *Science* 293(5534):1487–1491. doi:[10.1126/science.1058189](https://doi.org/10.1126/science.1058189)
142. Jin M, Shepardson N, Yang T, Chen G, Walsh D, Selkoe DJ (2011) Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. *Proc Natl Acad Sci USA* 108(14):5819–5824. doi:[10.1073/pnas.1017033108](https://doi.org/10.1073/pnas.1017033108)
143. Choi SH, Kim YH, Hebisch M, Sliwinski C, Lee S, D'Avanzo C, Chen H, Hooli B, Asselin C, Muffat J, Klee JB, Zhang C, Wainger BJ, Peitz M, Kovacs DM, Woolf CJ, Wagner SL, Tanzi RE, Kim DY (2014) A three-dimensional human neural cell culture model of Alzheimer's disease. *Nature* 515(7526):274–278. doi:[10.1038/nature13800](https://doi.org/10.1038/nature13800)
144. Koronyo Y, Salumbides BC, Sheyn J, Pelissier L, Li S, Ljubimov V, Moysseyev M, Daley D, Fuchs DT, Pham M, Black KL, Rentsendorj A, Koronyo-Hamaoui M (2015) Therapeutic effects of glatiramer acetate and grafted CD115(+) monocytes in a mouse model of Alzheimer's disease. *Brain J Neurol* 138(Pt 8):2399–2422. doi:[10.1093/brain/awv150](https://doi.org/10.1093/brain/awv150)
145. Bernstein KE, Koronyo Y, Salumbides BC, Sheyn J, Pelissier L, Lopes DH, Shah KH, Bernstein EA, Fuchs DT, Yu JJ, Pham M, Black KL, Shen XZ, Fuchs S, Koronyo-Hamaoui M (2014) Angiotensin-converting enzyme overexpression in myelomonocytes prevents Alzheimer's-like cognitive decline. *J Clin Invest* 124(3):1000–1012. doi:[10.1172/JCI66541](https://doi.org/10.1172/JCI66541)
146. Lebson L, Nash K, Kamath S, Herber D, Carty N, Lee DC, Li Q, Szekeres K, Jinwal U, Koren J, Dickey CA, Gottschall PE, Morgan D, Gordon MN (2010) Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. *J Neurosci* 30(29):9651–9658. doi:[10.1523/jneurosci.0329-10.2010](https://doi.org/10.1523/jneurosci.0329-10.2010)
147. Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A (2016) The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. *Nature* 537(7618):50–56. doi:[10.1038/nature19323](https://doi.org/10.1038/nature19323)
148. Koronyo-Hamaoui M, Ko MK, Koronyo Y, Azoulay D, Seksenyan A, Kunis G, Pham M, Bakhsheshian J, Rogeri P, Black KL, Farkas DL, Schwartz M (2009) Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. *J Neurochem* 111(6):1409–1424. doi:[10.1111/j.1471-4159.2009.06402.x](https://doi.org/10.1111/j.1471-4159.2009.06402.x)
149. Mormino EC, Sperling RA, Holmes AJ, Buckner RL, De Jager PL, Smoller JW, Sabuncu MR (2016) Polygenic risk of Alzheimer disease is associated with early- and late-life processes. *Neurology*. doi:[10.1212/wnl.0000000000002922](https://doi.org/10.1212/wnl.0000000000002922)
150. Grant WB, Campbell A, Itzhaki RF, Savory J (2002) The significance of environmental factors in the etiology of Alzheimer's disease. *JAD* 4(3):179–189
151. Farrer LA, Cupples L, Haines JL et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein e genotype and alzheimer disease: a meta-analysis. *JAMA* 278(16):1349–1356. doi:[10.1001/jama.1997.03550160069041](https://doi.org/10.1001/jama.1997.03550160069041)
152. Li J, Kanekiyo T, Shinohara M, Zhang Y, LaDu MJ, Xu H, Bu G (2012) Differential regulation of amyloid-beta endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. *J Biol Chem* 287(53):44593–44601. doi:[10.1074/jbc.M112.420224](https://doi.org/10.1074/jbc.M112.420224)
153. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J, Berk BC, Zlokovic BV (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. *Nature* 485(7399):512–516. doi:[10.1038/nature11087](https://doi.org/10.1038/nature11087)
154. Tai LM, Ghura S, Koster KP, Liakaite V, Maienschein-Cline M, Kanabar P, Collins N, Ben-Aissa M, Lei AZ, Bahroos N, Green SJ, Hendrickson B, Van Eldik LJ, LaDu MJ (2015) APOE-modulated Abeta-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. *J Neurochem* 133(4):465–488. doi:[10.1111/jnc.13072](https://doi.org/10.1111/jnc.13072)
155. Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogava E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J (2013) TREM2 variants in Alzheimer's disease. *N Engl J Med* 368(2):117–127. doi:[10.1056/NEJMoa1211851](https://doi.org/10.1056/NEJMoa1211851)
156. Malik M, Parikh I, Vasquez JB, Smith C, Tai L, Bu G, LaDu MJ, Fardo DW, Rebeck GW, Estus S (2015) Genetics ignite focus on microglial inflammation in Alzheimer's disease. *Mol Neurodegener* 10:52. doi:[10.1186/s13024-015-0048-1](https://doi.org/10.1186/s13024-015-0048-1)
157. Hooli BV, Parrado AR, Mullin K, Yip WK, Liu T, Roehr JT, Qiao D, Jessen F, Peters O, Becker T, Ramirez A, Lange C, Bertram L, Tanzi RE (2014) The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. *Neurology* 83(15):1353–1358. doi:[10.1212/wnl.0000000000000855](https://doi.org/10.1212/wnl.0000000000000855)
158. Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? *Nat Med* 12(9):1005–1015. doi:[10.1038/nm1484](https://doi.org/10.1038/nm1484)

159. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV (2000) Clearance of Alzheimer's amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. *J Clin Invest* 106(12):1489–1499. doi:[10.1172/jci10498](https://doi.org/10.1172/jci10498)
160. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO (2008) Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. *Brain Pathol* 18(2):253–266. doi:[10.1111/j.1750-3639.2008.00133.x](https://doi.org/10.1111/j.1750-3639.2008.00133.x)
161. Iliff JJ, Nedergaard M (2013) Is there a cerebral lymphatic system? *Stroke* 44(6 Suppl 1):S93–95. doi:[10.1161/strokeaha.112.678698](https://doi.org/10.1161/strokeaha.112.678698)
162. Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, Benveniste H, Vates GE, Deane R, Goldman SA, Nagelhus EA, Nedergaard M (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. *Sci Transl Med* 4(147):147ra111. doi:[10.1126/scitranslmed.3003748](https://doi.org/10.1126/scitranslmed.3003748)
163. Malm T, Koistinaho M, Muona A, Magga J, Koistinaho J (2010) The role and therapeutic potential of monocytic cells in Alzheimer's disease. *Glia* 58(8):889–900. doi:[10.1002/glia.20973](https://doi.org/10.1002/glia.20973)
164. Hemming ML, Selkoe DJ (2005) Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. *J Biol Chem* 280(45):37644–37650. doi:[10.1074/jbc.M508460200](https://doi.org/10.1074/jbc.M508460200)
165. Mukherjee A, Song E, Kihiko-Ehmann M, Goodman JP Jr, Pyrek JS, Estus S, Hersh LB (2000) Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques. *J Neurosci* 20(23):8745–8749
166. Kanemitsu H, Tomiyama T, Mori H (2003) Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. *Neurosci Lett* 350(2):113–116
167. Yin KJ, Cirrito JR, Yan P, Hu X, Xiao Q, Pan X, Bateman R, Song H, Hsu FF, Turk J, Xu J, Hsu CY, Mills JC, Holtzman DM, Lee JM (2006) Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. *J Neurosci* 26(43):10939–10948. doi:[10.1523/jneurosci.2085-06.2006](https://doi.org/10.1523/jneurosci.2085-06.2006)
168. Iwata N, Takaki Y, Fukami S, Tsubuki S, Saido TC (2002) Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. *J Neurosci Res* 70(3):493–500. doi:[10.1002/jnr.10390](https://doi.org/10.1002/jnr.10390)
169. Fukami S, Watanabe K, Iwata N, Haraoka J, Lu B, Gerard NP, Gerard C, Fraser P, Westaway D, St George-Hyslop P, Saido TC (2002) Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology. *Neurosci Res* 43(1):39–56
170. Hickman SE, Allison EK, El Khoury J (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. *J Neurosci* 28(33):8354–8360. doi:[10.1523/jneurosci.0616-08.2008](https://doi.org/10.1523/jneurosci.0616-08.2008)
171. Fisk L, Nalivaeva NN, Boyle JP, Peers CS, Turner AJ (2007) Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes. *Neurochem Res* 32(10):1741–1748. doi:[10.1007/s11064-007-9349-2](https://doi.org/10.1007/s11064-007-9349-2)
172. El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS (2008) Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. *Am J Pathol* 172(5):1342–1354. doi:[10.2353/ajpath.2008.070620](https://doi.org/10.2353/ajpath.2008.070620)
173. Parthasarathy R, Chow KM, Derafshi Z, Fautsch MP, Hetling JR, Rodgers DW, Hersh LB, Pepperberg DR (2015) Reduction of amyloid-beta levels in mouse eye tissues by intra-vitreally delivered neprilysin. *Exp Eye Res* 138:134–144. doi:[10.1016/j.exer.2015.06.027](https://doi.org/10.1016/j.exer.2015.06.027)
174. Kurochkin IV, Goto S (1994) Alzheimer's beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. *FEBS Lett* 345 (1):33–37
175. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. *J Biol Chem* 273(49):32730–32738
176. Bulloj A, Leal MC, Xu H, Castano EM, Morelli L (2010) Insulin-degrading enzyme sorting in exosomes: a secretory pathway for a key brain amyloid-beta degrading protease. *JAD* 19(1):79–95. doi:[10.3233/jad-2010-1206](https://doi.org/10.3233/jad-2010-1206)
177. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ (2000) Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. *J Neurosci* 20(5):1657–1665
178. Deb S, Zhang JW, Gottschall PE (1999) Activated isoforms of MMP-2 are induced in U87 human glioma cells in response to beta-amyloid peptide. *J Neurosci Res* 55(1):44–53
179. Fujioka H, Dairyo Y, Yasunaga K, Emoto K (2012) Neural functions of matrix metalloproteinases: plasticity, neurogenesis, and disease. *Biochem Res Int* 2012:789083. doi:[10.1155/2012/789083](https://doi.org/10.1155/2012/789083)
180. Terni B, Ferrer I (2015) Abnormal expression and distribution of MMP2 at initial stages of Alzheimer's disease-related pathology. *JAD* 46(2):461–469. doi:[10.3233/jad-142460](https://doi.org/10.3233/jad-142460)
181. Li W, Poteet E, Xie L, Liu R, Wen Y, Yang SH (2011) Regulation of matrix metalloproteinase 2 by oligomeric amyloid beta protein. *Brain Res* 1387:141–148. doi:[10.1016/j.brainres.2011.02.078](https://doi.org/10.1016/j.brainres.2011.02.078)
182. Roher AE, Kasunic TC, Woods AS, Cotter RJ, Ball MJ, Fridman R (1994) Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. *Biochem Biophys Res Commun* 205(3):1755–1761. doi:[10.1006/bbrc.1994.2872](https://doi.org/10.1006/bbrc.1994.2872)
183. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, Masters CL (2006) Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. *J Biol Chem* 281(26):17670–17680. doi:[10.1074/jbc.M602487200](https://doi.org/10.1074/jbc.M602487200)
184. Ito S, Kimura K, Haneda M, Ishida Y, Sawada M, Isobe K (2007) Induction of matrix metalloproteinases (MMP3, MMP12 and MMP13) expression in the microglia by amyloid-beta stimulation via the PI3K/Akt pathway. *Exp Gerontol* 42(6):532–537. doi:[10.1016/j.exger.2006.11.012](https://doi.org/10.1016/j.exger.2006.11.012)
185. Zhao L, Lin S, Bales KR, Gelfanova V, Koger D, DeLong C, Hale J, Liu F, Hunter JM, Paul SM (2009) Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism. *J Neurosci* 29(11):3603–3612. doi:[10.1523/jneurosci.5302-08.2009](https://doi.org/10.1523/jneurosci.5302-08.2009)
186. Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, Holtzman DM, Lee JM (2006) Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. *J Biol Chem* 281(34):24566–24574. doi:[10.1074/jbc.M602440200](https://doi.org/10.1074/jbc.M602440200)
187. Humpel C (2015) Organotypic vibrosections from whole brain adult Alzheimer mice (overexpressing amyloid-precursor-protein with the Swedish-Dutch-Iowa mutations) as a model to study clearance of beta-amyloid plaques. *Front Aging Neurosci* 7:47. doi:[10.3389/fnagi.2015.00047](https://doi.org/10.3389/fnagi.2015.00047)
188. Backstrom JR, Lim GP, Cullen MJ, Tokes ZA (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1–40). *J Neurosci* 16(24):7910–7919

189. Gottschall PE, Yu X, Bing B (1995) Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. *J Neurosci Res* 42(3):335–342. doi:10.1002/jnr.490420307
190. Muir EM, Adcock KH, Morgenstern DA, Clayton R, von Stillfried N, Rhodes K, Ellis C, Fawcett JW, Rogers JH (2002) Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes. *Brain Res Mol Brain Res* 100(1–2):103–117
191. Koronyo-Hamaoui M, Shah K, Koronyo Y, Bernstein E, Giani JF, Janjulia T, Black KL, Shi PD, Gonzalez-Villalobos RA, Fuchs S, Shen XZ, Bernstein KE (2014) ACE overexpression in myelomonocytic cells: effect on a mouse model of Alzheimer's disease. *Curr Hypertens Rep* 16(7):444. doi:10.1007/s11906-014-0444-x
192. Zou K, Maeda T, Watanabe A, Liu J, Liu S, Oba R, Satoh Y, Komano H, Michikawa M (2009) Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme. *J Biol Chem* 284(46):31914–31920. doi:10.1074/jbc.M109.011437
193. Russell FD, Skepper JN, Davenport AP (1998) Human endothelial cell storage granules: a novel intracellular site for isoforms of the endothelin-converting enzyme. *Circ Res* 83(3):314–321
194. Carty NC, Nash K, Lee D, Mercer M, Gottschall PE, Meyers C, Muzyczka N, Gordon MN, Morgan D (2008) Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice. *Mol Ther* 16(9):1580–1586. doi:10.1038/mt.2008.148
195. Eckman EA, Reed DK, Eckman CB (2001) Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. *J Biol Chem* 276(27):24540–24548. doi:10.1074/jbc.M007579200
196. Hook G, Yu J, Toneff T, Kindy M, Hook V (2014) Brain pyroglutamate amyloid-beta is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic. *Journal of Alzheimer's disease* : JAD 41(1):129–149. doi:10.3233/jad-131370
197. Hook V, Hook G, Kindy M (2010) Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. *Biol Chem* 391(8):861–872. doi:10.1515/bc.2010.110
198. Hook VY, Kindy M, Reinheckel T, Peters C, Hook G (2009) Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. *Biochem Biophys Res Commun* 386(2):284–288. doi:10.1016/j.bbrc.2009.05.131
199. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposito L, Mucke L, Gan L (2006) Anti-amyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. *Neuron* 51(6):703–714. doi:10.1016/j.neuron.2006.07.027
200. Cataldo AM, Nixon RA (1990) Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. *Proc Natl Acad Sci USA* 87(10):3861–3865
201. Wang C, Sun B, Zhou Y, Grubb A, Gan L (2012) Cathepsin B degrades amyloid-beta in mice expressing wild-type human amyloid precursor protein. *J Biol Chem* 287(47):39834–39841. doi:10.1074/jbc.M112.371641
202. Hamazaki H (1996) Cathepsin D is involved in the clearance of Alzheimer's beta-amyloid protein. *FEBS Lett* 396(2–3):139–142
203. Higaki J, Catalano R, Guzzetta AW, Quon D, Nave JF, Tarnus C, D'Orchymont H, Cordell B (1996) Processing of beta-amyloid precursor protein by cathepsin D. *J Biol Chem* 271(50):31885–31893
204. Lador US, Snyder SW, Wang GT, Holzman TF, Krafft GA (1994) Cleavage at the amino and carboxyl termini of Alzheimer's amyloid-beta by cathepsin D. *J Biol Chem* 269(28):18422–18428
205. Kehoe PG, Miners S, Love S (2009) Angiotensin in Alzheimer's disease—friend or foe? *Trends Neurosci* 32(12):619–628. doi:10.1016/j.tins.2009.07.006
206. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S, Kehoe PG (2008) Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. *Neuropathol Appl Neurobiol* 34(2):181–193. doi:10.1111/j.1365-2990.2007.00885.x
207. Miners S, Ashby E, Baig S, Harrison R, Tayler H, Speedy E, Prince JA, Love S, Kehoe PG (2009) Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. *Am J Transl Res* 1(2):163–177
208. Wang XB, Cui NH, Yang J, Qiu XP, Gao JJ, Yang N, Zheng F (2014) Angiotensin-converting enzyme insertion/deletion polymorphism is not a major determining factor in the development of sporadic Alzheimer disease: evidence from an updated meta-analysis. *PLoS One* 9(10):e111406. doi:10.1371/journal.pone.0111406
209. Zou K, Yamaguchi H, Akatsu H, Sakamoto T, Ko M, Mizoguchi K, Gong JS, Yu W, Yamamoto T, Kosaka K, Yanagisawa K, Michikawa M (2007) Angiotensin-converting enzyme converts amyloid beta-protein 1–42 (Abeta(1–42)) to Abeta(1–40), and its inhibition enhances brain Abeta deposition. *J Neurosci* 27(32):8628–8635. doi:10.1523/jneurosci.1549-07.2007
210. Miller BC, Eckman EA, Sambamurti K, Dobbs N, Chow KM, Eckman CB, Hersh LB, Thiele DL (2003) Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. *Proc Natl Acad Sci USA* 100(10):6221–6226. doi:10.1073/pnas.1031520100
211. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. *Neurobiol Aging* 26(5):645–654. doi:10.1016/j.neurobiolaging.2004.06.013
212. Miners JS, Baig S, Tayler H, Kehoe PG, Love S (2009) Nephilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. *J Neuropathol Exp Neurol* 68(8):902–914. doi:10.1097/NEN.0b013e3181afe475
213. Miners JS, van Helmond Z, Kehoe PG, Love S (2010) Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes nephilysin, insulin-degrading enzyme and angiotensin-converting enzyme. *Brain Pathol* 20(4):794–802. doi:10.1111/j.1750-3639.2010.00375.x
214. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Erickson S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS, Craft S (2003) Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. *Am J Pathol* 162(1):313–319
215. Fragkouli A, Tsilibary EC, Tzinia AK (2014) Neuroprotective role of MMP-9 overexpression in the brain of Alzheimer's 5xFAD mice. *Neurobiol Dis* 70:179–189. doi:10.1016/j.nbd.2014.06.021
216. Chong YH, Sung JH, Shin SA, Chung JH, Suh YH (2001) Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer's amyloid precursor protein on the production of the tumor necrosis factor-alpha and matrix metalloproteinase-9 by human monocytic THP-1. *J Biol Chem* 276(26):23511–23517. doi:10.1074/jbc.M009466200
217. Lee EJ, Moon PG, Baek MC, Kim HS (2014) Comparison of the effects of matrix metalloproteinase inhibitors on

- TNF-alpha release from activated microglia and TNF-alpha converting enzyme activity. *Biomol Ther (Seoul)* 22 (5):414–419. doi:10.4062/biomolther.2014.099
218. Yong VW, Power C, Forsyth P, Edwards DR (2001) Metalloproteinases in biology and pathology of the nervous system. *Nat Rev Neurosci* 2(7):502–511. doi:10.1038/35081571
219. de Castro RC Jr, Burns CL, McAdoo DJ, Romanic AM (2000) Metalloproteinase increases in the injured rat spinal cord. *Neuroreport* 11(16):3551–3554
220. Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, Kiryu-Seo S, Kiyama H, Iwata H, Tomita T, Iwatsubo T, Saido TC (2001) Neprilysin degrades both amyloid beta peptides 1–40 and 1–42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. *J Biol Chem* 276(24):21895–21901. doi:10.1074/jbc.M008511200
221. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. *Nat Med* 6(2):143–150. doi:10.1038/72237
222. Russo R, Borghi R, Markesbery W, Tabaton M, Piccini A (2005) Neprilysin decreases uniformly in Alzheimer's disease and in normal aging. *FEBS Lett* 579 (27):6027–6030. doi:10.1016/j.febslet.2005.09.054
223. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee HJ, Saido TC (2001) Metabolic regulation of brain Abeta by neprilysin. *Science* 292(5521):1550–1552. doi:10.1126/science.1059946
224. Huttenrauch M, Baches S, Gerth J, Bayer TA, Weggen S, Wirths O (2015) Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer's disease. *JAD* 44(4):1291–1302. doi:10.3233/jad-142463
225. Mouri A, Zou LB, Iwata N, Saido TC, Wang D, Wang MW, Noda Y, Nabeshima T (2006) Inhibition of neprilysin by thiorphan (i.c.v.) causes an accumulation of amyloid beta and impairment of learning and memory. *Behav Brain Res* 168(1):83–91. doi:10.1016/j.bbr.2005.10.014
226. Shimizu E, Kawahara K, Kajizono M, Sawada M, Nakayama H (2008) IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1–42) by rat primary type 2 microglia. *J Immunol (Baltimore, Md: 1950)* 181 (9):6503–6513
227. Bernstein KE, Gonzalez-Villalobos RA, Gianni JF, Shah K, Bernstein E, Janjulia T, Koronyo Y, Shi PD, Koronyo-Hamaoui M, Fuchs S, Shen XZ (2014) Angiotensin-converting enzyme overexpression in myelocytes enhances the immune response. *Biol Chem* 395(10):1173–1178. doi:10.1515/hsz-2013-0295
228. Gowrishankar S, Yuan P, Wu Y, Schrag M, Paradise S, Grutzendler J, De Camilli P, Ferguson SM (2015) Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques. *Proc Natl Acad Sci USA* 112(28):E3699–E3708. doi:10.1073/pnas.1510329112
229. Tian L, Zhang K, Tian ZY, Wang T, Shang DS, Li B, Liu DX, Fang WG, Wang ZY, Chen YH (2014) Decreased expression of cathepsin D in monocytes is related to the defective degradation of amyloid-beta in Alzheimer's disease. *JAD* 42(2):511–520. doi:10.3233/jad-132192
230. Nixon RA, Yang DS (2011) Autophagy failure in Alzheimer's disease—locating the primary defect. *Neurobiol Dis* 43(1):38–45. doi:10.1016/j.nbd.2011.01.021
231. Keller JN, Hanni KB, Markesbery WR (2000) Impaired proteasome function in Alzheimer's disease. *J Neurochem* 75(1):436–439
232. Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG (1998) Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. *J Neurosci Res* 52(6):691–698
233. Umeda T, Tomiyama T, Sakama N, Tanaka S, Lambert MP, Klein WL, Mori H (2011) Intraneuronal amyloid beta oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. *J Neurosci Res* 89(7):1031–1042. doi:10.1002/jnr.22640
234. Ji ZS, Mullendorff K, Cheng IH, Miranda RD, Huang Y, Mahley RW (2006) Reactivity of apolipoprotein E4 and amyloid beta peptide: lysosomal stability and neurodegeneration. *J Biol Chem* 281(5):2683–2692. doi:10.1074/jbc.M506646200
235. Brunk U, Brun A (1972) The effect of aging on lysosomal permeability in nerve cells of the central nervous system. An enzyme histochemical study in rat. *Histochemie* 30(4):315–324
236. Ji ZS, Miranda RD, Newhouse YM, Weisgraber KH, Huang Y, Mahley RW (2002) Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells. *J Biol Chem* 277(24):21821–21828. doi:10.1074/jbc.M112109200
237. Echeverria V, Ducatenzeiler A, Dowd E, Janne J, Grant SM, Szyf M, Wandosell F, Avila J, Grimm H, Dunnett SB, Hartmann T, Alhonen L, Cuello AC (2004) Altered mitogen-activated protein kinase signaling, tau hyperphosphorylation and mild spatial learning dysfunction in transgenic rats expressing the beta-amyloid peptide intracellularly in hippocampal and cortical neurons. *Neuroscience* 129(3):583–592. doi:10.1016/j.neuroscience.2004.07.036
238. Oh S, Hong HS, Hwang E, Sim HJ, Lee W, Shin SJ, Mook-Jung I (2005) Amyloid peptide attenuates the proteasome activity in neuronal cells. *Mech Ageing Dev* 126(12):1292–1299. doi:10.1016/j.mad.2005.07.006
239. Frackowiak J, Wisniewski HM, Wegiel J, Merz GS, Iqbal K, Wang KC (1992) Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. *Acta Neuropathol (Berl)* 84(3):225–233
240. Paresce DM, Chung H, Maxfield FR (1997) Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. *J Biol Chem* 272(46):29390–29397
241. Majumdar A, Chung H, Dolios G, Wang R, Asamoah N, Lobel P, Maxfield FR (2008) Degradation of fibrillar forms of Alzheimer's amyloid beta-peptide by macrophages. *Neurobiol Aging* 29(5):707–715. doi:10.1016/j.neurobiolaging.2006.12.001
242. Dahms NM, Lobel P, Kornfeld S (1989) Mannose 6-phosphate receptors and lysosomal enzyme targeting. *J Biol Chem* 264(21):12115–12118
243. Tiribuzi R, Crispoltoni L, Porcellati S, Di Lullo M, Florenzano F, Pirro M, Bagaglia F, Kawarai T, Zampolini M, Orlacchio A, Orlacchio A (2014) miR128 up-regulation correlates with impaired amyloid beta(1–42) degradation in monocytes from patients with sporadic Alzheimer's disease. *Neurobiol Aging* 35(2):345–356. doi:10.1016/j.neurobiolaging.2013.08.003
244. Koga H, Cuervo AM (2011) Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration. *Neurobiol Dis* 43(1):29–37. doi:10.1016/j.nbd.2010.07.006
245. Zare-Shahabadi A, Masliah E, Johnson GV, Rezaei N (2015) Autophagy in Alzheimer's disease. *Rev Neurosci* 26(4):385–395. doi:10.1515/revneuro-2014-0076
246. Stromhaug PE, Berg TO, Fengsrud M, Seglen PO (1998) Purification and characterization of autophagosomes from rat hepatocytes. *Biochem J* 335(Pt 2):217–224
247. Son SM, Jung ES, Shin HJ, Byun J, Mook-Jung I (2012) Abeta-induced formation of autophagosomes is mediated by RAGE-CaMKKbeta-AMPK signaling. *Neurobiol Aging* 33(5):1006.e1011–1023. doi:10.1016/j.neurobiolaging.2011.09.039

248. Tian Y, Chang JC, Greengard P, Flajolet M (2014) The convergence of endosomal and autophagosomal pathways: implications for APP-CTF degradation. *Autophagy* 10(4):694–696. doi:10.4161/auto.27802
249. Boland B, Kumar A, Lee S, Platt FM, Wegiel J, Yu WH, Nixon RA (2008) Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. *J Neurosci* 28(27):6926–6937. doi:10.1523/jneurosci.0800-08.2008
250. Nixon RA (2007) Autophagy, amyloidogenesis and Alzheimer disease. *J Cell Sci* 120(Pt 23):4081–4091. doi:10.1242/jcs.019265
251. Correia SC, Resende R, Moreira PI, Pereira CM (2015) Alzheimer's disease-related misfolded proteins and dysfunctional organelles on autophagy menu. *DNA Cell Biol* 34 (4):261–273. doi:10.1089/dna.2014.2757
252. Lipinski MM, Zheng B, Lu T, Yan Z, Py BF, Ng A, Xavier RJ, Li C, Yankner BA, Scherzer CR, Yuan J (2010) Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. *Proc Natl Acad Sci USA* 107(32):14164–14169. doi:10.1073/pnas.1009485107
253. Nilsson P, Loganathan K, Sekiguchi M, Matsuba Y, Hui K, Tsubuki S, Tanaka M, Iwata N, Saito T, Saido TC (2013) Abeta secretion and plaque formation depend on autophagy. *Cell Rep* 5(1):61–69. doi:10.1016/j.celrep.2013.08.042
254. Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R, Jaeger PA, Small S, Spencer B, Rockenstein E, Levine B, Wyss-Coray T (2008) The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. *J Clin Invest* 118(6):2190–2199. doi:10.1172/jci33585
255. Jung CH, Ro SH, Cao J, Otto NM, Kim DH (2010) mTOR regulation of autophagy. *FEBS Lett* 584 (7):1287–1295. doi:10.1016/j.febslet.2010.01.017
256. Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, Ohsumi Y, Tokuhiya T, Mizushima N (2004) The role of autophagy during the early neonatal starvation period. *Nature* 432(7020):1032–1036. doi:10.1038/nature03029
257. Scherz-Shouval R, Elazar Z (2007) ROS, mitochondria and the regulation of autophagy. *Trends Cell Biol* 17(9):422–427. doi:10.1016/j.tcb.2007.07.009
258. Li X, Alafuzoff I, Soininen H, Winblad B, Pei JJ (2005) Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. *FEBS J* 272(16):4211–4220. doi:10.1111/j.1742-4658.2005.04833.x
259. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, Richardson A, Strong R, Galvan V (2010) Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. *PLoS one* 5(4):e9979. doi:10.1371/journal.pone.0009979
260. Keller JN, Gee J, Ding Q (2002) The proteasome in brain aging. *Ageing Res Rev* 1(2):279–293
261. Lopez Salom M, Morelli L, Castano EM, Soto EF, Pasquini JM (2000) Defective ubiquitination of cerebral proteins in Alzheimer's disease. *J Neurosci Res* 62(2):302–310. doi:10.1002/1097-4547(20001015)62:2<302::aid-jnr15>3.0.co;2-I
262. Hiltunen M, Lu A, Thomas AV, Romano DM, Kim M, Jones PB, Xie Z, Kounnas MZ, Wagner SL, Berezovska O, Hyman BT, Tesco G, Bertram L, Tanzi RE (2006) Ubiquitin 1 modulates amyloid precursor protein trafficking and Abeta secretion. *J Biol Chem* 281(43):32240–32253. doi:10.1074/jbc.M603106200
263. Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM (2008) Abeta inhibits the proteasome and enhances amyloid and tau accumulation. *Neurobiol Aging* 29(11):1607–1618. doi:10.1016/j.neurobiolaging.2007.04.014
264. Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel L, Rusinek H, Nicholson C, Zlokovic BV, Frangione B, Blennow K, Menard J, Zetterberg H, Wisniewski T, de Leon MJ (2015) Clearance systems in the brain-implications for Alzheimer disease. *Nat Rev Neurol* 11(8):457–470. doi:10.1038/nrneuro.2015.119
265. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. *Neuron* 43(3):333–344. doi:10.1016/j.neuron.2004.07.017
266. Elali A, Rivest S (2013) The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease. *Front Physiol* 4:45. doi:10.3389/fphys.2013.00045
267. Jaeger LB, Dohgu S, Hwang MC, Farr SA, Murphy MP, Fleegal-DeMotta MA, Lynch JL, Robinson SM, Niehoff ML, Johnson SN, Kumar VB, Banks WA (2009) Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. *JAD* 17(3):553–570. doi:10.3233/jad-2009-1074
268. Silverberg GD, Messier AA, Miller MC, Machan JT, Majumdar SS, Stopa EG, Donahue JE, Johanson CE (2010) Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. *J Neuropathol Exp Neurol* 69(10):1034–1043. doi:10.1097/NEN.0b013e3181f46e25
269. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. *Nat Med* 10(7):719–726. doi:10.1038/nm1058
270. Laporte V, Lombard Y, Levy-Benezra R, Tranchant C, Pointron P, Warter JM (2004) Uptake of Abeta 1-40- and Abeta 1-42-coated yeast by microglial cells: a role for LRP. *J Leukocyte Biol* 76(2):451–461. doi:10.1189/jlb.1203620
271. Kanekiyo T, Cirrito JR, Liu CC, Shinohara M, Li J, Schuler DR, Shinohara M, Holtzman DM, Bu G (2013) Neuronal clearance of amyloid-beta by endocytic receptor LRP1. *J Neurosci* 33(49):19276–19283. doi:10.1523/jneurosci.3487-13.2013
272. Baig S, Joseph SA, Tayler H, Abraham R, Owen MJ, Williams J, Kehoe PG, Love S (2010) Distribution and expression of picalm in Alzheimer disease. *J Neuropathol Exp Neurol* 69(10):1071–1077. doi:10.1097/NEN.0b013e3181f52e01
273. Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglia GD, Zou F, Crook JE, Pankratz VS, Dickson DW, Graff-Radford NR, Petersen RC, Morgan K, Younkin SG (2010) Replication of CLU, CR1, and PICALM associations with Alzheimer disease. *Arch Neurol* 67(8):961–964. doi:10.1001/archneurol.2010.147
274. Zhao Z, Sagare AP, Ma Q, Halliday MR, Kong P, Kisler K, Winkler EA, Ramanathan A, Kanekiyo T, Bu G, Owens NC, Rege SV, Si G, Ahuja A, Zhu D, Miller CA, Schneider JA, Maeda M, Maeda T, Sugawara T, Ichida JK, Zlokovic BV (2015) Central role for PICALM in amyloid-beta blood-brain barrier transcytosis and clearance. *Nat Neurosci* 18(7):978–987. doi:10.1038/nn.4025
275. Mahley RW (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. *Science* 240(4852):622–630
276. Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK (1989) The LDL-receptor-related protein, LRP, is an

- apolipoprotein E-binding protein. *Nature* 341(6238):162–164. doi:[10.1038/341162a0](https://doi.org/10.1038/341162a0)
277. Kim DH, Iijima H, Goto K, Sakai J, Ishii H, Kim HJ, Suzuki H, Kondo H, Saeki S, Yamamoto T (1996) Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. *J Biol Chem* 271(14):8373–8380
278. Kanekiyo T, Xu H, Bu G (2014) ApoE and Abeta in Alzheimer's disease: accidental encounters or partners? *Neuron* 81(4):740–754. doi:[10.1016/j.neuron.2014.01.045](https://doi.org/10.1016/j.neuron.2014.01.045)
279. Raber J, Huang Y, Ashford JW (2004) ApoE genotype accounts for the vast majority of AD risk and AD pathology. *Neurobiol Aging* 25(5):641–650. doi:[10.1016/j.neurobiolaging.2003.12.023](https://doi.org/10.1016/j.neurobiolaging.2003.12.023)
280. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM (2000) Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci USA* 97(6):2892–2897. doi:[10.1073/pnas.050004797](https://doi.org/10.1073/pnas.050004797)
281. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. *Proc Natl Acad Sci USA* 90(20):9649–9653
282. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc Natl Acad Sci USA* 90(5):1977–1981
283. Shinohara M, Petersen RC, Dickson DW, Bu G (2013) Brain regional correlation of amyloid-beta with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-beta accumulation. *Acta Neuropathol (Berl)* 125(4):535–547. doi:[10.1007/s00401-013-1086-9](https://doi.org/10.1007/s00401-013-1086-9)
284. Mulder SD, Nielsen HM, Blankenstein MA, Eikelenboom P, Veerhuis R (2014) Apolipoproteins E and J interfere with amyloid-beta uptake by primary human astrocytes and microglia in vitro. *Glia* 62(4):493–503. doi:[10.1002/glia.22619](https://doi.org/10.1002/glia.22619)
285. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA (2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. *Ann Neurol* 67(1):122–131. doi:[10.1002/ana.21843](https://doi.org/10.1002/ana.21843)
286. LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE (1994) Isoform-specific binding of apolipoprotein E to beta-amyloid. *J Biol Chem* 269(38):23403–23406
287. Wildsmith KR, Holley M, Savage JC, Skerrett R, Landreth GE (2013) Evidence for impaired amyloid beta clearance in Alzheimer's disease. *Alzheimer's Res Ther* 5(4):33. doi:[10.1186/alzrt187](https://doi.org/10.1186/alzrt187)
288. Donahue JE, Johanson CE (2008) Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. *J Neuropathol Exp Neurol* 67(4):261–270. doi:[10.1097/NEN.0b013e31816a0dc8](https://doi.org/10.1097/NEN.0b013e31816a0dc8)
289. Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M (2011) Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. *J Biol Chem* 286(20):17536–17542. doi:[10.1074/jbc.M111.225532](https://doi.org/10.1074/jbc.M111.225532)
290. Rodriguez GA, Tai LM, LaDu MJ, Rebeck GW (2014) Human APOE4 increases microglia reactivity at Abeta plaques in a mouse model of Abeta deposition. *J Neuroinflamm* 11:111. doi:[10.1186/1742-2094-11-111](https://doi.org/10.1186/1742-2094-11-111)
291. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, O'Donnell J, Christensen DJ, Nicholson C, Iliff JJ, Takano T, Deane R, Nedergaard M (2013) Sleep drives metabolite clearance from the adult brain. *Science* 342(6156):373–377. doi:[10.1126/science.1241224](https://doi.org/10.1126/science.1241224)
292. Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J (2015) Structural and functional features of central nervous system lymphatic vessels. *Nature* 523(7560):337–341. doi:[10.1038/nature14432](https://doi.org/10.1038/nature14432)
293. Aspelund A, Antila S, Proulx ST, Karlsten TV, Karaman S, Detmar M, Wiig H, Alitalo K (2015) A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. *J Exp Med* 212(7):991–999. doi:[10.1084/jem.20142290](https://doi.org/10.1084/jem.20142290)
294. Kress BT, Iliff JJ, Xia M, Wang M, Wei HS, Zeppenfeld D, Xie L, Kang H, Xu Q, Liew JA, Plog BA, Ding F, Deane R, Nedergaard M (2014) Impairment of paravascular clearance pathways in the aging brain. *Ann Neurol* 76(6):845–861. doi:[10.1002/ana.24271](https://doi.org/10.1002/ana.24271)
295. Malm TM, Koistinaho M, Parepalo M, Vatanen T, Ooka A, Karlsson S, Koistinaho J (2005) Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. *Neurobiol Dis* 18(1):134–142. doi:[10.1016/j.nbd.2004.09.009](https://doi.org/10.1016/j.nbd.2004.09.009)
296. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S (2006) Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. *Neuron* 49(4):489–502. doi:[10.1016/j.neuron.2006.01.022](https://doi.org/10.1016/j.neuron.2006.01.022)
297. Butovsky O, Kunis G, Koronyo-Hamaoui M, Schwartz M (2007) Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. *Eur J Neurosci* 26(2):413–416. doi:[10.1111/j.1460-9568.2007.05652.x](https://doi.org/10.1111/j.1460-9568.2007.05652.x)
298. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. *Nat Med* 13(4):432–438. doi:[10.1038/nm1555](https://doi.org/10.1038/nm1555)
299. Paresce DM, Ghosh RN, Maxfield FR (1996) Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. *Neuron* 17(3):553–565
300. Chung H, Brazil MI, Soe TT, Maxfield FR (1999) Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. *J Biol Chem* 274(45):32301–32308
301. Priller J, Flugel A, Wehner T, Boentert M, Haas CA, Prinz M, Fernandez-Klett F, Prass K, Bechmann I, de Boer BA, Frotscher M, Kreutzberg GW, Persons DA, Dirnagl U (2001) Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. *Nat Med* 7(12):1356–1361. doi:[10.1038/nm1201-1356](https://doi.org/10.1038/nm1201-1356)
302. Sedgwick JD, Schwender S, Imrich H, Dorries R, Butcher GW, ter Meulen V (1991) Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. *Proc Natl Acad Sci USA* 88(16):7438–7442
303. Prinz M, Priller J, Sisodia SS, Ransohoff RM (2011) Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. *Nat Neurosci* 14(10):1227–1235. doi:[10.1038/nn.2923](https://doi.org/10.1038/nn.2923)
304. Ford AL, Goodsall AL, Hickey WF, Sedgwick JD (1995) Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4 + T cells compared. *J Immunol (Baltimore, Md: 1950)* 154(9):4309–4321

305. Juedes AE, Ruddle NH (2001) Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. *J Immunol* (Baltimore, Md: 1950) 166(8):5168–5175
306. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z, Rothstein JD, Ransohoff RM, Gygi SP, Antel JP, Weiner HL (2014) Identification of a unique TGF-beta-dependent molecular and functional signature in microglia. *Nat Neurosci* 17(1):131–143. doi:10.1038/nn.3599
307. Prinz M, Priller J (2014) Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. *Nat Rev Neurosci* 15(5):300–312. doi:10.1038/nrn3722
308. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K (2010) Development of monocytes, macrophages, and dendritic cells. *Science* 327(5966):656–661. doi:10.1126/science.1178331
309. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, Guiducci E, Dumas L, Ragozzino D, Gross CT (2011) Synaptic pruning by microglia is necessary for normal brain development. *Science* 333(6048):1456–1458. doi:10.1126/science.1202529
310. Chung WS, Welsh CA, Barres BA, Stevens B (2015) Do glia drive synaptic and cognitive impairment in disease? *Nat Neurosci* 18(11):1539–1545. doi:10.1038/nn.4142
311. Naert G, Rivest S (2013) A deficiency in CCR2 + monocytes: the hidden side of Alzheimer's disease. *J Mol Cell Biol* 5(5):284–293. doi:10.1093/jmcb/mjt028
312. Yamamoto M, Kiyota T, Walsh SM, Liu J, Kipnis J, Ikezu T (2008) Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. *J Immunol* (Baltimore, Md: 1950) 181(6):3877–3886
313. Hu N, Tan MS, Sun L, Jiang T, Wang YL, Tan L, Zhang W, Yu JT, Tan L (2014) Decreased expression of CD33 in peripheral mononuclear cells of Alzheimer's disease patients. *Neurosci Lett* 563:51–54. doi:10.1016/j.neulet.2014.01.004
314. Zhang R, Miller RG, Madison C, Jin X, Honrada R, Harris W, Katz J, Forshew DA, McGrath MS (2013) Systemic immune system alterations in early stages of Alzheimer's disease. *J Neuroimmunol* 256(1–2):38–42. doi:10.1016/j.jneuroim.2013.01.002
315. Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, Sayre J, Zhang L, Zaghi J, Dejbakhsh S, Chiang B, Hui J, Mahanian M, Baghaee A, Hong P, Cashman J (2007) Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. *Proc Natl Acad Sci USA* 104(31):12849–12854. doi:10.1073/pnas.0701267104
316. Plagg B, Ehrlich D, Kniewallner KM, Marksteiner J, Humpel C (2015) Increased acetylation of histone H4 at lysine 12 (H4K12) in monocytes of transgenic Alzheimer's mice and in human patients. *Curr Alzheimer Res* 12(8):752–760
317. Lunnon K, Ibrahim Z, Proitsi P, Lourdasamy A, Newhouse S, Sattler M, Furney S, Saleem M, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Coppola G, Geschwind D, Simmons A, Lovestone S, Dobson R, Hodges A (2012) Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. *JAD* 30(3):685–710. doi:10.3233/jad-2012-111592
318. Stalder AK, Ermini F, Bondolfi L, Krenger W, Burbach GJ, Deller T, Coomaraswamy J, Staufenbiel M, Landmann R, Jucker M (2005) Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. *J Neurosci* 25(48):11125–11132. doi:10.1523/jneurosci.2545-05.2005
319. Keene CD, Chang RC, Lopez-Yglesias AH, Shalloway BR, Sokal I, Li X, Reed PJ, Keene LM, Montine KS, Breyer RM, Rockhill JK, Montine TJ (2010) Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. *Am J Pathol* 177(1):346–354. doi:10.2353/ajpath.2010.090840
320. Naert G, Rivest S (2012) Age-related changes in synaptic markers and monocyte subsets link the cognitive decline of APP(Swe)/PS1 mice. *Front Cell Neurosci* 6:51. doi:10.3389/fncel.2012.00051
321. Boissonneault V, Filali M, Lessard M, Relton J, Wong G, Rivest S (2009) Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. *Brain J Neurol* 132(Pt 4):1078–1092. doi:10.1093/brain/awn331
322. Town T, Laouar Y, Pittenger C, Mori T, Szekeley CA, Tan J, Duman RS, Flavell RA (2008) Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. *Nat Med* 14(6):681–687. doi:10.1038/nm1781
323. Jiang T, Tan L, Zhu XC, Zhang QQ, Cao L, Tan MS, Gu LZ, Wang HF, Ding ZZ, Zhang YD, Yu JT (2014) Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease. *Neuropsychopharmacology* 39(13):2949–2962. doi:10.1038/npp.2014.164
324. Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT (2015) TREM2 deficiency eliminates TREM2 + inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. *J Exp Med* 212(3):287–295. doi:10.1084/jem.20142322
325. Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel I, Kleinberger G, Haass C (2016) TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. *EMBO Mol Med*. doi:10.15252/emmm.201606370
326. Frenkel D, Wilkinson K, Zhao L, Hickman SE, Means TK, Puckett L, Farfara D, Kingery ND, Weiner HL, El Khoury J (2013) Scara1 deficiency impairs clearance of soluble amyloid-beta by mononuclear phagocytes and accelerates Alzheimer's-like disease progression. *Nature Commun* 4:2030. doi:10.1038/ncomms3030
327. Yamamoto M, Kiyota T, Walsh SM, Ikezu T (2007) Kinetic analysis of aggregated amyloid-beta peptide clearance in adult bone-marrow-derived macrophages from APP and CCL2 transgenic mice. *J Neuroimmune Pharmacol* 2(2):213–221. doi:10.1007/s11481-006-9049-8
328. Hawkes CA, McLaurin J (2009) Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. *Proc Natl Acad Sci USA* 106(4):1261–1266. doi:10.1073/pnas.0805453106
329. Michaud JP, Bellavance MA, Prefontaine P, Rivest S (2013) Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta. *Cell Rep* 5(3):646–653. doi:10.1016/j.celrep.2013.10.010
330. Mildner A, Schlevogt B, Kierdorf K, Bottcher C, Erny D, Kummer MP, Quinn M, Bruck W, Bechmann I, Heneka MT, Priller J, Prinz M (2011) Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. *J Neurosci* 31(31):11159–11171. doi:10.1523/jneurosci.6209-10.2011
331. Naert G, Rivest S (2011) CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. *J Neurosci* 31(16):6208–6220. doi:10.1523/jneurosci.0299-11.2011

332. Yang CN, Shiao YJ, Shie FS, Guo BS, Chen PH, Cho CY, Chen YJ, Huang FL, Tsay HJ (2011) Mechanism mediating oligomeric Abeta clearance by naive primary microglia. *Neurobiol Dis* 42(3):221–230. doi:[10.1016/j.nbd.2011.01.005](https://doi.org/10.1016/j.nbd.2011.01.005)
333. Mandrekar S, Jiang Q, Lee CY, Koenigsnecht-Talboo J, Holtzman DM, Landreth GE (2009) Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. *J Neurosci* 29(13):4252–4262. doi:[10.1523/jneurosci.5572-08.2009](https://doi.org/10.1523/jneurosci.5572-08.2009)
334. Koenigsnecht J, Landreth G (2004) Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. *J Neurosci* 24(44):9838–9846. doi:[10.1523/jneurosci.2557-04.2004](https://doi.org/10.1523/jneurosci.2557-04.2004)
335. Grathwohl SA, Kalin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S, Aguzzi A, Staufenbiel M, Mathews PM, Wolburg H, Heppner FL, Jucker M (2009) Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. *Nat Neurosci* 12(11):1361–1363. doi:[10.1038/nn.2432](https://doi.org/10.1038/nn.2432)
336. Spangenberg EE, Green KN (2016) Inflammation in Alzheimer's disease: Lessons learned from microglia-depletion models. *Brain Behav Immun*. doi:[10.1016/j.bbi.2016.07.003](https://doi.org/10.1016/j.bbi.2016.07.003)
337. Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U, Miller KR, Prokop S, Kettenmann H, Heppner FL (2013) Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. *PloS One* 8(4):e60921. doi:[10.1371/journal.pone.0060921](https://doi.org/10.1371/journal.pone.0060921)
338. Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, Klunk WE, Kohsaka S, Jucker M, Calhoun ME (2008) Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. *J Neurosci* 28(16):4283–4292. doi:[10.1523/jneurosci.4814-07.2008](https://doi.org/10.1523/jneurosci.4814-07.2008)
339. Hellwig S, Masuch A, Nestel S, Katzmarski N, Meyer-Luehmann M, Biber K (2015) Forebrain microglia from wild-type but not adult 5xFAD mice prevent amyloid-beta plaque formation in organotypic hippocampal slice cultures. *Sci Rep* 5:14624. doi:[10.1038/srep14624](https://doi.org/10.1038/srep14624)
340. Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease—a brief review of the basic science and clinical literature. *Cold Spring Harb Perspect Med* 2(1):a006346. doi:[10.1101/cshperspect.a006346](https://doi.org/10.1101/cshperspect.a006346)
341. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mucke M, Mucke PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. *Neurobiol Aging* 21(3):383–421
342. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT (1998) Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. *Am J Pathol* 153(1):31–37
343. Takeuchi H, Jin S, Wang J, Zhang G, Kawanokuchi J, Kuno R, Sonobe Y, Mizuno T, Suzumura A (2006) Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. *J Biol Chem* 281(30):21362–21368. doi:[10.1074/jbc.M600504200](https://doi.org/10.1074/jbc.M600504200)
344. Wyss-Coray T, Mucke L (2002) Inflammation in neurodegenerative disease—a double-edged sword. *Neuron* 35(3):419–432
345. Lopez-Gonzalez I, Schluter A, Aso E, Garcia-Esparcia P, Ansoleaga B, F LL, Carmona M, Moreno J, Fusco A, Portero-Otin M, Pamplona R, Pujol A, Ferrer I (2015) Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: correlations with plaques, tangles, and oligomeric species. *J Neuropathol Exp Neurol* 74(4):319–344. doi:[10.1097/nen.0000000000000176](https://doi.org/10.1097/nen.0000000000000176)
346. Rice RA, Spangenberg EE, Yamate-Morgan H, Lee RJ, Arora RP, Hernandez MX, Tenner AJ, West BL, Green KN (2015) Elimination of microglia improves functional outcomes following extensive neuronal loss in the hippocampus. *J Neurosci* 35(27):9977–9989. doi:[10.1523/jneurosci.0336-15.2015](https://doi.org/10.1523/jneurosci.0336-15.2015)
347. Spangenberg EE, Lee RJ, Najafi AR, Rice RA, Elmore MR, Blurton-Jones M, West BL, Green KN (2016) Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-beta pathology. *Brain J Neurol* 139(Pt 4):1265–1281. doi:[10.1093/brain/aww016](https://doi.org/10.1093/brain/aww016)
348. Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, Cohen H, Schwartz M (2006) Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. *Proc Natl Acad Sci USA* 103(31):11784–11789. doi:[10.1073/pnas.0604681103](https://doi.org/10.1073/pnas.0604681103)
349. Condello C, Yuan P, Schain A, Grutzendler J (2015) Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. *Nature Commun* 6:6176. doi:[10.1038/ncomms7176](https://doi.org/10.1038/ncomms7176)
350. Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES, Tsai LH (2016) Gamma frequency entrainment attenuates amyloid load and modifies microglia. *Nature* 540(7632):230–235. doi:[10.1038/nature20587](https://doi.org/10.1038/nature20587)
351. Michell-Robinson MA, Touil H, Healy LM, Owen DR, Dura-four BA, Bar-Or A, Antel JP, Moore CS (2015) Roles of microglia in brain development, tissue maintenance and repair. *Brain J Neurol* 138(Pt 5):1138–1159. doi:[10.1093/brain/awv066](https://doi.org/10.1093/brain/awv066)
352. Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, Bruck W, Priller J, Prinz M (2007) Microglia in the adult brain arise from Ly-6ChiCCR2 + monocytes only under defined host conditions. *Nat Neurosci* 10(12):1544–1553. doi:[10.1038/nn2015](https://doi.org/10.1038/nn2015)
353. Prokop S, Miller KR, Drost N, Handrick S, Mathur V, Luo J, Wegner A, Wyss-Coray T, Heppner FL (2015) Impact of peripheral myeloid cells on amyloid-beta pathology in Alzheimer's disease-like mice. *J Exp Med* 212(11):1811–1818. doi:[10.1084/jem.20150479](https://doi.org/10.1084/jem.20150479)
354. Varvel NH, Grathwohl SA, Degenhardt K, Resch C, Bosch A, Jucker M, Neher JJ (2015) Replacement of brain-resident myeloid cells does not alter cerebral amyloid-beta deposition in mouse models of Alzheimer's disease. *J Exp Med* 212(11):1803–1809. doi:[10.1084/jem.20150478](https://doi.org/10.1084/jem.20150478)
355. Ajami B, Bennett JL, Kriegler C, Tetzlaff W, Rossi FM (2007) Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. *Nat Neurosci* 10(12):1538–1543. doi:[10.1038/nn2014](https://doi.org/10.1038/nn2014)
356. Zaghi J, Goldenson B, Inayathullah M, Lossinsky AS, Masoumi A, Avagyan H, Mahanian M, Bernas M, Weinand M, Rosenthal MJ, Espinosa-Jeffrey A, de Vellis J, Teplow DB, Fiala M (2009) Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. *Acta Neuropathol (Berl)* 117(2):111–124. doi:[10.1007/s00401-008-0481-0](https://doi.org/10.1007/s00401-008-0481-0)
357. Ard MD, Cole GM, Wei J, Mehrle AP, Fratkin JD (1996) Scavenging of Alzheimer's amyloid beta-protein by microglia in culture. *J Neurosci Res* 43(2):190–202. doi:[10.1002/\(SICI\)1097-4547\(19960115\)43:2<190::AID-JNR7>3.0.CO;2-B](https://doi.org/10.1002/(SICI)1097-4547(19960115)43:2<190::AID-JNR7>3.0.CO;2-B)
358. Frautschy SA, Cole GM, Baird A (1992) Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. *Am J Pathol* 140(6):1389–1399
359. Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, O'Hare E, Esler WP, Maggio JE, Mantyh PW (1998) Fibrillar

- beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. *J Neurosci* 18(6):2161–2173
360. Akiyama H, Schwab C, Kondo H, Mori H, Kametani F, Ikeda K, McGeer PL (1996) Granules in glial cells of patients with Alzheimer's disease are immunopositive for C-terminal sequences of beta-amyloid protein. *Neurosci Lett* 206(2–3):169–172
361. Wilkinson K, Boyd JD, Glicksman M, Moore KJ, El Khoury J (2011) A high content drug screen identifies ursolic acid as an inhibitor of amyloid beta protein interactions with its receptor CD36. *J Biol Chem* 286(40):34914–34922. doi:10.1074/jbc.M111.232116
362. Udan ML, Ajit D, Crouse NR, Nichols MR (2008) Toll-like receptors 2 and 4 mediate Abeta(1–42) activation of the innate immune response in a human monocytic cell line. *J Neurochem* 104(2):524–533. doi:10.1111/j.1471-4159.2007.05001.x
363. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE (2009) CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. *J Neurosci* 29(38):11982–11992. doi:10.1523/jneurosci.3158-09.2009
364. Hughes DA, Fraser IP, Gordon S (1995) Murine macrophage scavenger receptor: in vivo expression and function as receptor for macrophage adhesion in lymphoid and non-lymphoid organs. *Eur J Immunol* 25(2):466–473. doi:10.1002/eji.1830250224
365. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JD (1996) Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. *Nature* 382(6593):716–719. doi:10.1038/382716a0
366. Chung H, Brazil MI, Irizarry MC, Hyman BT, Maxfield FR (2001) Uptake of fibrillar beta-amyloid by microglia isolated from MSR-A (type I and type II) knockout mice. *Neuroreport* 12(6):1151–1154
367. Bakalash S, Pham M, Koronyo Y, Salumbides BC, Kramerov A, Seidenberg H, Berel D, Black KL, Koronyo-Hamaoui M (2011) Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease. *Investig Ophthalmol Vis Sci* 52(12):9033–9046. doi:10.1167/iovs.11-7498
368. Wilkinson K, El Khoury J (2012) Microglial scavenger receptors and their roles in the pathogenesis of Alzheimer's disease. *Int J Alzheimers Dis* 2012:489456. doi:10.1155/2012/489456
369. Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M, Schnell L, Sommer B, Jucker M, Staufenbiel M (2001) Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. *Am J Pathol* 158(1):63–73
370. Christie RH, Freeman M, Hyman BT (1996) Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. *Am J Pathol* 148(2):399–403
371. Yu Y, Ye RD (2015) Microglial Abeta receptors in Alzheimer's disease. *Cell Mol Neurobiol* 35(1):71–83. doi:10.1007/s10571-014-0101-6
372. El Khoury JB, Moore KJ, Means TK, Leung J, Terada K, Toft M, Freeman MW, Luster AD (2003) CD36 mediates the innate host response to beta-amyloid. *J Exp Med* 197(12):1657–1666. doi:10.1084/jem.20021546
373. Sheedy FJ, Grebe A, Rayner KJ, Kalantari P, Ramkhalawon B, Carpenter SB, Becker CE, Ediriweera HN, Mullick AE, Golenbock DT, Stuart LM, Latz E, Fitzgerald KA, Moore KJ (2013) CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. *Nat Immunol* 14(8):812–820. doi:10.1038/ni.2639
374. Pan XD, Zhu YG, Lin N, Zhang J, Ye QY, Huang HP, Chen XC (2011) Microglial phagocytosis induced by fibrillar beta-amyloid is attenuated by oligomeric beta-amyloid: implications for Alzheimer's disease. *Mol Neurodegener* 6:45. doi:10.1186/1750-1326-6-45
375. Daws MR, Sullam PM, Niemi EC, Chen TT, Tchao NK, Seaman WE (2003) Pattern recognition by TREM-2: binding of anionic ligands. *J Immunol (Baltimore, Md: 1950)* 171(2):594–599
376. Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robi-nette ML, Gilfillan S, Krishnan GM, Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR, Colonna M (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. *Cell* 160(6):1061–1071. doi:10.1016/j.cell.2015.01.049
377. Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M (2016) TREM2 binds to apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of amyloid-beta by microglia. *Neuron* 91(2):328–340. doi:10.1016/j.neuron.2016.06.015
378. Bouchon A, Hernandez-Munain C, Cella M, Colonna M (2001) A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. *J Exp Med* 194(8):1111–1122
379. Malik M, Simpson JF, Parikh I, Wilfred BR, Fardo DW, Nelson PT, Estus S (2013) CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing. *J Neurosci* 33(33):13320–13325. doi:10.1523/jneurosci.1224-13.2013
380. Pillai S, Netravali IA, Cariappa A, Mattoo H (2012) Siglecs and immune regulation. *Annu Rev Immunol* 30:357–392. doi:10.1146/annurev-immunol-020711-075018
381. Diserbo M, Agin A, Lamproglou I, Mauris J, Staali F, Mul-ton E, Amourette C (2002) Blood-brain barrier permeability after gamma whole-body irradiation: an in vivo microdialysis study. *Can J Physiol Pharmacol* 80(7):670–678
382. Wegiel J, Imaki H, Wang KC, Wegiel J, Rubenstein R (2004) Cells of monocyte/microglial lineage are involved in both microvessel amyloidosis and fibrillar plaque formation in APPsw tg mice. *Brain Res* 1022(1–2):19–29. doi:10.1016/j.brainres.2004.06.058
383. Wegiel J, Imaki H, Wang KC, Wegiel J, Wronska A, Osuchowski M, Rubenstein R (2003) Origin and turnover of microglial cells in fibrillar plaques of APPsw transgenic mice. *Acta Neuropathol (Berl)* 105(4):393–402. doi:10.1007/s00401-002-0660-3
384. Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. *J Interferon Cytokine Res* 29(6):313–326. doi:10.1089/jir.2008.0027
385. Conduictier G, Blondeau N, Guyon A, Nahon JL, Rovere C (2010) The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. *J Neuroimmunol* 224(1–2):93–100. doi:10.1016/j.jneuroim.2010.05.010
386. Perlmutt LS (1994) Microvascular pathology and vascular basement membrane components in Alzheimer's disease. *Mol Neurobiol* 9(1–3):33–40. doi:10.1007/bf02816103
387. Algotsson A, Winblad B (2007) The integrity of the blood-brain barrier in Alzheimer's disease. *Acta Neurol Scand* 115(6):403–408. doi:10.1111/j.1600-0404.2007.00823.x
388. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF (2007) Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. *Neurology* 68(21):1809–1814. doi:10.1212/01.wnl.0000262031.18018.1a
389. Meda L, Bernasconi S, Bonaiuto C, Sozzani S, Zhou D, Otvos L, Jr., Mantovani A, Rossi F, Cassatella MA (1996) Beta-amyloid (25–35) peptide and IFN-gamma synergistically induce the production of the chemotactic cytokine MCP-1/JE in monocytes

- and microglial cells. *J Immunol* (Baltimore, Md: 1950) 157 (3):1213–1218
390. London A, Cohen M, Schwartz M (2013) Microglia and monocyte-derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair. *Front Cell Neurosci* 7:34. doi:[10.3389/fncel.2013.00034](https://doi.org/10.3389/fncel.2013.00034)
391. Shechter R, Raposo C, London A, Sagi I, Schwartz M (2011) The glial scar-monocyte interplay: a pivotal resolution phase in spinal cord repair. *PLoS One* 6(12):e27969. doi:[10.1371/journal.pone.0027969](https://doi.org/10.1371/journal.pone.0027969)
392. Huang D, Wujek J, Kidd G, He TT, Cardona A, Sasse ME, Stein EJ, Kish J, Tani M, Charo IF, Proudfoot AE, Rollins BJ, Handel T, Ransohoff RM (2005) Chronic expression of monocyte chemoattractant protein-1 in the central nervous system causes delayed encephalopathy and impaired microglial function in mice. *FASEB J* 19(7):761–772. doi:[10.1096/fj.04-3104com](https://doi.org/10.1096/fj.04-3104com)
393. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. *CNS Neurol Disord Drug Targ* 8(1):16–30
394. Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V (2012) Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. *Proc Natl Acad Sci USA* 109(9):3510–3515. doi:[10.1073/pnas.1112209109](https://doi.org/10.1073/pnas.1112209109)
395. Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park JS, Couillard-Despres S, Aigner L, Li G, Peskind ER, Kaye JA, Quinn JF, Galasko DR, Xie XS, Rando TA, Wyss-Coray T (2011) The ageing systemic milieu negatively regulates neurogenesis and cognitive function. *Nature* 477(7362):90–94. doi:[10.1038/nature10357](https://doi.org/10.1038/nature10357)
396. Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, Smith LK, Bieri G, Lin K, Berdnik D, Wabl R, Udeochu J, Wheatley EG, Zou B, Simmons DA, Xie XS, Longo FM, Wyss-Coray T (2014) Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. *Nat Med* 20(6):659–663. doi:[10.1038/nm.3569](https://doi.org/10.1038/nm.3569)
397. Xiang Y, Bu XL, Liu YH, Zhu C, Shen LL, Jiao SS, Zhu XY, Giunta B, Tan J, Song WH, Zhou HD, Zhou XF, Wang YJ (2015) Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease. *Acta Neuropathol (Berl)* 130(4):487–499. doi:[10.1007/s00401-015-1477-1](https://doi.org/10.1007/s00401-015-1477-1)
398. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kaye R, Glabe CG, Frautschy SA, Cole GM (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. *J Biol Chem* 280(7):5892–5901. doi:[10.1074/jbc.M404751200](https://doi.org/10.1074/jbc.M404751200)
399. Zhang L, Fiala M, Cashman J, Sayre J, Espinosa A, Mahanian M, Zaghi J, Badmaev V, Graves MC, Bernard G, Rosenthal M (2006) Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients. *JAD* 10(1):1–7
400. Baruch K, Deczkowska A, Rosenzweig N, Tsitsou-Kampeli A, Sharif AM, Matcovitch-Natan O, Kertser A, David E, Amit I, Schwartz M (2016) PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease. *Nat Med* 22(2):135–137. doi:[10.1038/nm.4022](https://doi.org/10.1038/nm.4022)